<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="febs70033" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">FEBS J</journal-id><journal-id journal-id-type="iso-abbrev">FEBS J</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1742-4658</journal-id><journal-id journal-id-type="publisher-id">FEBS</journal-id><journal-title-group><journal-title>The Febs Journal</journal-title></journal-title-group><issn pub-type="ppub">1742-464X</issn><issn pub-type="epub">1742-4658</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40022434</article-id><article-id pub-id-type="pmc">PMC12103066</article-id>
<article-id pub-id-type="doi">10.1111/febs.70033</article-id><article-id pub-id-type="publisher-id">FEBS70033</article-id><article-id pub-id-type="other">FJ-24-0448.R1</article-id><article-categories><subj-group subj-group-type="article-subject-classification"><subject>RNA Modification</subject></subj-group><subj-group subj-group-type="article-subject-classification"><subject>Breast Cancer</subject></subj-group><subj-group subj-group-type="article-subject-classification"><subject>RNA Biology</subject></subj-group><subj-group subj-group-type="article-subject-classification"><subject>Extracellular Matrix</subject></subj-group><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The <styled-content style="fixed-case" toggle="no">m6A</styled-content> demethylase <styled-content style="fixed-case" toggle="no">FTO</styled-content> promotes C/<styled-content style="fixed-case" toggle="no">EBP&#x003b2;</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">LIP</styled-content> translation to perform oncogenic functions in breast cancer cells</article-title><alt-title alt-title-type="right-running-head">FTO upregulates C/EBP&#x003b2;&#x02010;LIP in breast cancer cells</alt-title><alt-title alt-title-type="left-running-head">H. R. Zuidhof <italic toggle="no">et&#x000a0;al.</italic>
</alt-title></title-group><contrib-group><contrib id="febs70033-cr-0001" contrib-type="author"><name><surname>Zuidhof</surname><given-names>Hidde R.</given-names></name><xref rid="febs70033-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="febs70033-cr-0002" contrib-type="author"><name><surname>M&#x000fc;ller</surname><given-names>Christine</given-names></name><xref rid="febs70033-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="febs70033-cr-0003" contrib-type="author"><name><surname>Kortman</surname><given-names>Gertrud</given-names></name><xref rid="febs70033-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="febs70033-cr-0004" contrib-type="author"><name><surname>Wardenaar</surname><given-names>Ren&#x000e9;</given-names></name><xref rid="febs70033-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="febs70033-cr-0005" contrib-type="author"><name><surname>Stepanova</surname><given-names>Ekaterina</given-names></name><xref rid="febs70033-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="febs70033-cr-0006" contrib-type="author"><name><surname>Loayza&#x02010;Puch</surname><given-names>Fabricio</given-names></name><xref rid="febs70033-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="febs70033-cr-0007" contrib-type="author" corresp="yes"><name><surname>Calkhoven</surname><given-names>Cornelis F.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6318-7210</contrib-id><xref rid="febs70033-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>c.f.calkhoven@umcg.nl</email></address></contrib></contrib-group><aff id="febs70033-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">European Institute for the Biology of Ageing (ERIBA)</named-content>
<institution>University Medical Center Groningen, University of Groningen</institution>
<country country="NL">The Netherlands</country>
</aff><aff id="febs70033-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Translational Control and Metabolism</named-content>
<institution>German Cancer Research Center (DKFZ)</institution>
<city>Heidelberg</city>
<country country="DE">Germany</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
C. F. Calkhoven, ERIBA, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.<break/>
Tel: +31 6 52 72 45 91<break/>
E&#x02010;mail: <email>c.f.calkhoven@umcg.nl</email>
<break/>
Website: <ext-link xlink:href="https://eriba.umcg.nl/people/cor-calkhoven/" ext-link-type="uri">https://eriba.umcg.nl/people/cor&#x02010;calkhoven/</ext-link>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2025</year></pub-date><volume>292</volume><issue seq="150">10</issue><issue-id pub-id-type="doi">10.1111/febs.v292.10</issue-id><fpage>2688</fpage><lpage>2709</lpage><history>
<date date-type="rev-recd"><day>04</day><month>10</month><year>2024</year></date>
<date date-type="received"><day>30</day><month>4</month><year>2024</year></date>
<date date-type="accepted"><day>30</day><month>12</month><year>2024</year></date>
</history><permissions><!--Copyright &#x000a9; 2025 Federation of European Biochemical Societies--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">The FEBS Journal</italic> published by John Wiley &#x00026; Sons Ltd on behalf of Federation of European Biochemical Societies.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:FEBS-292-2688.pdf"/><abstract><p>N6&#x02010;methyladenosine (m6A) is a prevalent posttranscriptional mRNA modification involved in the regulation of transcript turnover, translation, and other aspects of RNA fate. The modification is mediated by multicomponent methyltransferase complexes (so&#x02010;called writers) and is reversed through the action of the m6A&#x02010;demethylases fat mass and obesity&#x02010;associated (FTO) and alkB homolog 5 (ALKBH5) (so&#x02010;called erasers). FTO promotes cell proliferation, colony formation and metastasis in models of triple&#x02010;negative breast cancer (TNBC). However, little is known about genome&#x02010;wide or specific downstream regulation by FTO. Here, we examined changes in the genome&#x02010;wide transcriptome and translatome following FTO knockdown in TNBC cells. Unexpectedly, FTO knockdown had a limited effect on the translatome, while transcriptome analysis revealed that genes related to extracellular matrix (ECM) and epithelial&#x02010;mesenchymal transition (EMT) are regulated through yet unidentified mechanisms. Differential translation of CEBPB mRNA into the C/EBP&#x003b2; transcription factor isoform C/EBP&#x003b2;&#x02010;LIP is known to act in a pro&#x02010;oncogenic manner in TNBC cells through regulation of EMT genes. Here we show that FTO is required for efficient C/EBP&#x003b2;&#x02010;LIP expression, suggesting that FTO has oncogenic functions through regulation of C/EBP&#x003b2;&#x02010;LIP.</p></abstract><abstract abstract-type="graphical"><p>N6&#x02010;methyladenosine is a key mRNA modification that regulates transcript turnover, translation, and other aspects of RNA fate. The m6A&#x02010;demethylase &#x02018;eraser&#x02019; enzyme FTO reverses this modification. While FTO is known to promote oncogenic signaling in triple&#x02010;negative breast cancer, its wider role across the genome and specific downstream signaling has yet to be explored. Here, we investigated the changes in the genome&#x02010;wide transcriptome and translatome associated with FTO in triple&#x02010;negative breast cancer and identified the CEBPB mRNA as a critical downstream target.<boxed-text position="anchor" content-type="graphic" id="febs70033-blkfxd-0001"><graphic xlink:href="FEBS-292-2688-g004.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="febs70033-kwd-0001">breast cancer</kwd><kwd id="febs70033-kwd-0002">C/EBP&#x003b2;</kwd><kwd id="febs70033-kwd-0003">FTO</kwd><kwd id="febs70033-kwd-0004">mRNA translation</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>European Research Council
</institution><institution-id institution-id-type="doi">10.13039/501100000781</institution-id></institution-wrap></funding-source><award-id>759579</award-id></award-group><award-group id="funding-0002"><funding-source><institution-wrap><institution>Deutsche Forschungsgemeinschaft
</institution><institution-id institution-id-type="doi">10.13039/501100001659</institution-id></institution-wrap></funding-source><award-id>504774163</award-id><award-id>545215964</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>KWF Kankerbestrijding
</institution><institution-id institution-id-type="doi">10.13039/501100004622</institution-id></institution-wrap></funding-source><award-id>10080</award-id></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Boehringer Ingelheim
</institution><institution-id institution-id-type="doi">10.13039/100001003</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="11"/><table-count count="1"/><page-count count="22"/><word-count count="14248"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.6 mode:remove_FC converted:24.05.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body id="febs70033-body-0001"><def-list list-content="abbreviations" id="febs70033-dl-0001"><title>Abbreviations</title><def-item><term id="febs70033-li-0001">(Me)RIP</term><def id="febs70033-li-0002"><p>(methylated&#x02010;)RNA immunoprecipitation</p></def></def-item><def-item><term id="febs70033-li-0003">ALKBH5</term><def id="febs70033-li-0004"><p>alkB homolog 5</p></def></def-item><def-item><term id="febs70033-li-0005">C/EBP (CEBPB)</term><def id="febs70033-li-0006"><p>CCAAT enhancer binding protein (the gene)</p></def></def-item><def-item><term id="febs70033-li-0007">ECM</term><def id="febs70033-li-0008"><p>extracellular matrix</p></def></def-item><def-item><term id="febs70033-li-0009">EMT</term><def id="febs70033-li-0010"><p>epithelial&#x02010;mesenchymal transition</p></def></def-item><def-item><term id="febs70033-li-0011">FTO</term><def id="febs70033-li-0012"><p>fat mass and obesity&#x02010;associated</p></def></def-item><def-item><term id="febs70033-li-0013">LAP</term><def id="febs70033-li-0014"><p>Liver&#x02010;enriched activating protein (translational isoform of C/EBP&#x003b2;)</p></def></def-item><def-item><term id="febs70033-li-0015">LIP</term><def id="febs70033-li-0016"><p>Liver&#x02010;enriched inhibitory protein (translational isoform of C/EBP&#x003b2;)</p></def></def-item><def-item><term id="febs70033-li-0017">m6A</term><def id="febs70033-li-0018"><p>N6&#x02010;methyladenosine</p></def></def-item><def-item><term id="febs70033-li-0019">METTL</term><def id="febs70033-li-0020"><p>methyltransferase&#x02010;like</p></def></def-item><def-item><term id="febs70033-li-0021">RT&#x02010;qPCR</term><def id="febs70033-li-0022"><p>real time reverse transcription polymerase chain reaction.</p></def></def-item><def-item><term id="febs70033-li-0023">TNBC</term><def id="febs70033-li-0024"><p>triple&#x02010;negative breast cancer</p></def></def-item><def-item><term id="febs70033-li-0025">WTAP</term><def id="febs70033-li-0026"><p>Wilms' tumor 1&#x02010;associated protein</p></def></def-item></def-list><sec id="febs70033-sec-0001"><title>Introduction</title><p>
<italic toggle="yes">N</italic>
<sup>6</sup>&#x02010;Methyladenosine (m6A) is the most prevalent modification of mammalian mRNA and is involved in multiple steps of gene regulation [<xref rid="febs70033-bib-0001" ref-type="bibr">1</xref>, <xref rid="febs70033-bib-0002" ref-type="bibr">2</xref>]. m6A modification is performed by a methyltransferase complex consisting of methyltransferase&#x02010;like 3 (METTL3), METTL14 and multiple accessory proteins including Wilms' tumor 1&#x02010;associating protein (WTAP), and is most often found in the 3&#x02032; untranslated region (3&#x02032;UTR) and tends to occur at RRACH (R&#x02009;=&#x02009;G or A; H&#x02009;=&#x02009;A, C or U) consensus motifs [<xref rid="febs70033-bib-0003" ref-type="bibr">3</xref>, <xref rid="febs70033-bib-0004" ref-type="bibr">4</xref>, <xref rid="febs70033-bib-0005" ref-type="bibr">5</xref>, <xref rid="febs70033-bib-0006" ref-type="bibr">6</xref>, <xref rid="febs70033-bib-0007" ref-type="bibr">7</xref>]. m6A modification may destabilize mRNA through binding of YTH domain containing family proteins 1&#x02013;3 (YTHDF1&#x02010;3) [<xref rid="febs70033-bib-0008" ref-type="bibr">8</xref>, <xref rid="febs70033-bib-0009" ref-type="bibr">9</xref>], or if found in the coding region may regulate mRNA translation [<xref rid="febs70033-bib-0010" ref-type="bibr">10</xref>, <xref rid="febs70033-bib-0011" ref-type="bibr">11</xref>, <xref rid="febs70033-bib-0012" ref-type="bibr">12</xref>]. However, the transcriptome&#x02010;wide effects of m6A on translation and the involvement of YTHDF1 are disputed [<xref rid="febs70033-bib-0013" ref-type="bibr">13</xref>, <xref rid="febs70033-bib-0014" ref-type="bibr">14</xref>].</p><p>Two mammalian demethylases are known: fat mass and obesity&#x02010;associated (FTO) and alkB homolog 5 (ALKBH5) [<xref rid="febs70033-bib-0015" ref-type="bibr">15</xref>, <xref rid="febs70033-bib-0016" ref-type="bibr">16</xref>]. Both are ubiquitously expressed but their targets and biological functions appear to differ. <italic toggle="yes">Alkbh5</italic>&#x02010;knockout mice are anatomically normal but less fertile due to erroneous splicing and rapid degradation of genes involved in spermatogenesis [<xref rid="febs70033-bib-0016" ref-type="bibr">16</xref>, <xref rid="febs70033-bib-0017" ref-type="bibr">17</xref>]. <italic toggle="yes">Fto</italic>&#x02010;knockout mice on the other hand are smaller with less lean mass and adipose tissue while no reduction in fertility has been reported [<xref rid="febs70033-bib-0018" ref-type="bibr">18</xref>]. In humans, single nucleotide polymorphisms (SNPs) in the <italic toggle="yes">FTO</italic> gene are the strongest genetic link with obesity in genome&#x02010;wide association studies (GWAS) [<xref rid="febs70033-bib-0019" ref-type="bibr">19</xref>]. More recently, FTO was shown to play a role in many types of cancer, both with oncogenic and tumor suppressive functions depending on tumor type and/or stage [<xref rid="febs70033-bib-0020" ref-type="bibr">20</xref>]. Mostly, FTO was found to act as an oncogene, for example in acute myeloid leukemia (AML) subtypes [<xref rid="febs70033-bib-0021" ref-type="bibr">21</xref>, <xref rid="febs70033-bib-0022" ref-type="bibr">22</xref>], breast cancer [<xref rid="febs70033-bib-0023" ref-type="bibr">23</xref>] and glioma [<xref rid="febs70033-bib-0024" ref-type="bibr">24</xref>].</p><p>Triple&#x02010;negative breast cancer (TNBC) encompasses 10&#x02013;15% of all breast tumors and is characterized by loss of estrogen and progesterone receptor expression and a lack of HER2 amplification, which are therefore not available as therapeutic targets [<xref rid="febs70033-bib-0025" ref-type="bibr">25</xref>]. TNBC has a poor prognosis with an overall 5&#x02010;year relapse of approximately 40% due to metastatic spread [<xref rid="febs70033-bib-0026" ref-type="bibr">26</xref>]. To be able to migrate to distant sites tumor cells have to undergo epithelial to mesenchymal transition (EMT) [<xref rid="febs70033-bib-0027" ref-type="bibr">27</xref>]. Cell migration processes are regulated by genes involved in extracellular matrix modulation, cell adhesion regulation, and actin cytoskeleton mobilization [<xref rid="febs70033-bib-0028" ref-type="bibr">28</xref>].</p><p>In tumor samples of breast cancer patients, high expression of the C/EBP&#x003b2; transcription factor protein isoform C/EBP&#x003b2;&#x02010;LIP correlates with loss of estrogen/progesterone receptor expression, a high Ki&#x02010;67 proliferative index, and lack of differentiation [<xref rid="febs70033-bib-0029" ref-type="bibr">29</xref>, <xref rid="febs70033-bib-0030" ref-type="bibr">30</xref>, <xref rid="febs70033-bib-0031" ref-type="bibr">31</xref>]. Previously, we showed that C/EBP&#x003b2;&#x02010;LIP induces cancer&#x02010;type metabolic reprogramming through the induction of aerobic glycolysis to sustain cell growth [<xref rid="febs70033-bib-0032" ref-type="bibr">32</xref>] and promotes EMT gene expression as well as migration and invasion of breast cancer cells and untransformed epithelial cells [<xref rid="febs70033-bib-0033" ref-type="bibr">33</xref>]. Three C/EBP&#x003b2; protein isoforms are expressed from the CEBPB mRNA through differential translation. The protein isoforms designated C/EBP&#x003b2;&#x02010;LAP1 and C/EBP&#x003b2;&#x02010;LAP2 (liver&#x02010;enriched activating proteins) are expressed through regular translation. These are transcriptional activators containing N&#x02010;terminal transcriptional transactivation domains and a C&#x02010;terminal basic DNA&#x02010;binding and leucine&#x02010;zipper dimerization domain (bZIP) [<xref rid="febs70033-bib-0031" ref-type="bibr">31</xref>, <xref rid="febs70033-bib-0034" ref-type="bibr">34</xref>]. The expression of C/EBP&#x003b2;&#x02010;LIP (liver&#x02010;enriched inhibitory protein) is strictly dependent on the initial translation of a <italic toggle="yes">cis</italic>&#x02010;regulatory small upstream open reading frame (uORF) and successive translation reinitiation from a downstream translation initiation site (for a detailed explanation, see [<xref rid="febs70033-bib-0031" ref-type="bibr">31</xref>]). The C/EBP&#x003b2;&#x02010;LIP isoform lacks the transactivation domains but does bind to DNA through the bZIP domain [<xref rid="febs70033-bib-0035" ref-type="bibr">35</xref>]. C/EBP&#x003b2;&#x02010;LIP translation is stimulated by the nutrient and energy sensing mTORC1&#x02010;4E&#x02010;BP&#x02010;eIF4E pathway, while its expression is restricted when mTORC1 signaling is suppressed and/or when under stress conditions activation of eIF&#x02010;2&#x003b1;&#x02010;kinases prevents reloading of post&#x02010;uORF ribosomes with initiator Met&#x02010;tRNA<sub>i</sub>
<sup>Met</sup> [<xref rid="febs70033-bib-0031" ref-type="bibr">31</xref>].</p><p>The molecular mechanisms and downstream targets of FTO's function in breast cancer growth and migration remain largely unexplored. We hypothesized that FTO may contribute to these processes through regulation of general mRNA translation and/or specific mRNA translation, the latter exemplified by translation of CEBPB mRNA. To reveal the genome&#x02010;wide effects of FTO expression in TNBC, we performed transcriptome and ribosome profiling experiments. While FTO knockdown hardly affected the translatome, transcriptome analysis revealed the regulation of several genes involved in extracellular matrix (ECM) and epithelial&#x02010;mesenchymal transition (EMT). Similar results were obtained by treatment with the catechol&#x02010;<italic toggle="yes">O</italic>&#x02010;methyltransferase and the FTO inhibitor entacapone. In addition, our data show that FTO knockdown affects C/EBP&#x003b2;&#x02010;LIP expression, decreasing the C/EBP&#x003b2;&#x02010;LIP/LAP ratio, while knockdown of the m6A&#x02010;methyltransferase complex component WTAP increases C/EBP&#x003b2;&#x02010;LIP expression. Furthermore, we show that in TNBC cells ectopic expression of LIP rescues the migration defect caused by FTO knockdown, suggesting that LIP is involved in FTO&#x02010;mediated cell migration.</p></sec><sec sec-type="results" id="febs70033-sec-0002"><title>Results</title><sec id="febs70033-sec-0003"><title>
<styled-content style="fixed-case" toggle="no">FTO</styled-content> facilitates breast cancer cell proliferation and migration</title><p>We examined the effect of FTO knockdown on the proliferation and migration of the breast cancer cell lines MDA&#x02010;MB&#x02010;231 (triple&#x02010;negative breast cancer) and MCF&#x02010;7 (luminal A type metastatic adenocarcinoma) using short hairpin lentiviral vectors (shFTO). FTO knockdown resulted in the expected general increase in the m6A loading of mRNAs, as measured by m6A&#x02010;mRNA dot blotting (Fig.&#x000a0;<xref rid="febs70033-fig-0001" ref-type="fig">1A</xref>), while it did not affect the expression of the other known m6A demethylase ALKBH5 (Fig.&#x000a0;<xref rid="febs70033-fig-0001" ref-type="fig">1B</xref>). In a clonogenic assay, cell proliferation was significantly reduced upon FTO knockout in MDA&#x02010;MB&#x02010;231 and MCF&#x02010;7 cells (Fig.&#x000a0;<xref rid="febs70033-fig-0002" ref-type="fig">2A</xref>). The effect of FTO knockdown on the migration of MDA&#x02010;MB&#x02010;231 cells was measured using a Boyden chamber (Transwell migration) assay (Fig.&#x000a0;<xref rid="febs70033-fig-0002" ref-type="fig">2B</xref>) and by live&#x02010;cell imaging scratch wound assays using the IncuCyte system (Sartorius) (Fig.&#x000a0;<xref rid="febs70033-fig-0002" ref-type="fig">2C</xref>). Both assays showed reduced cell migration upon FTO knockdown. Moreover, stable re&#x02010;expression of FTO in FTO&#x02010;knockdown MDA&#x02010;MB&#x02010;231 cells resulted in rescue of the Transwell migration (Fig.&#x000a0;<xref rid="febs70033-fig-0002" ref-type="fig">2D</xref>). In addition, treatment with the FTO inhibitor entacapone caused a dose&#x02010;dependent decrease in cell proliferation in both MDA&#x02010;MB&#x02010;231 and MCF&#x02010;7 cells (Fig.&#x000a0;<xref rid="febs70033-fig-0002" ref-type="fig">2E</xref>) and caused a reduction in MDA&#x02010;MB&#x02010;231 Transwell migration (Boyden chamber) (Fig.&#x000a0;<xref rid="febs70033-fig-0002" ref-type="fig">2F</xref>). Finally, FTO knockdown in the untransformed MCF10A breast epithelial cell line inhibited cell proliferation and Transwell migration in the presence of growth factors (Fig.&#x000a0;<xref rid="febs70033-fig-0003" ref-type="fig">3A&#x02013;C</xref>). Together, these data and data from another laboratory [<xref rid="febs70033-bib-0023" ref-type="bibr">23</xref>] show that the m6A&#x02010;demethylase FTO promotes proliferation and migration in breast cancer cells.</p><fig position="float" fig-type="Fig." id="febs70033-fig-0001"><label>Fig. 1</label><caption><p>FTO knockdown increases m6A loading of mRNAs. (A) m6A dot blot of 100&#x02009;ng mRNA from MDA&#x02010;MB&#x02010;231 cells or 150&#x02009;ng mRNA from MCF&#x02010;7 cells with FTO knockdown (shFTO1 or shFTO2) versus scrambled&#x02010;shRNA (scr) control. The blots shown are representative of 3 biological replicates used for quantification of m6A signal relative to scr control shown beneath the blot. Methylene blue staining is shown as loading control. (B) RT&#x02010;qPCR analysis of <italic toggle="yes">FTO</italic> and <italic toggle="yes">ALKBH5</italic> gene expression in MDA&#x02010;MB&#x02010;231 or MCF&#x02010;7 cells with FTO knockdown (shFTO1 or shFTO2) versus scrambled&#x02010;shRNA control (scr). Values are normalized to scr control per gene. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (mean&#x02009;&#x000b1;&#x02009;SD, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates).</p></caption><graphic xlink:href="FEBS-292-2688-g003" position="anchor" id="jats-graphic-3"/></fig><fig position="float" fig-type="Fig." id="febs70033-fig-0002"><label>Fig. 2</label><caption><p>FTO knockdown impairs breast cancer cell proliferation and migration. (A) Clonogenic assay of MDA&#x02010;MB&#x02010;231 and MCF&#x02010;7 cells with FTO knockdown (shFTO1) or scrambled control (scr). Cells were harvested and stained after 7&#x02009;days in cell culture. Quantification for two independent knockdown constructs (shFTO1 and shFTO2) is shown in the middle. At the right, immunoblots showing FTO expression levels in FTO knockdown cells and scr control cells, and &#x003b2;&#x02010;Actin was used as loading control. Values are shown as mean (&#x02212;) and individual data points (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3); significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (B) Transwell migration assay of MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1 or shFTO2) or scrambled control (scr) at 48&#x02009;h. Scale bar represents 500&#x02009;&#x003bc;m. Quantification is shown at the right. Values are shown as mean (&#x02212;) and individual data points (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3); significance determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (C) Time course of live&#x02010;cell imaging scratch wound assays using IncuCyte (Sartorius) of MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1 or shFTO2) or scrambled control (scr). Scale bar represents 300&#x02009;&#x003bc;m. Quantification is shown at the right. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01 (mean&#x02009;&#x000b1;&#x02009;SEM, <italic toggle="yes">n</italic>&#x02009;=&#x02009;4 biological replicates). (D) Transwell migration assay of MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1) with re&#x02010;expression of FTO or empty vector (EV) control at 48&#x02009;h. Scale bar represents 500&#x02009;&#x003bc;m. Quantification of cell migration is shown as mean (&#x02212;) and individual data points (<italic toggle="yes">n</italic>&#x02009;=&#x02009;6, technical replicates); significance was determined by Student's <italic toggle="yes">t</italic>&#x02010;test, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05. At the right immunoblots showing FTO re&#x02010;expression or empty vector (EV) control in FTO knockdown MDA&#x02010;MB&#x02010;231 cells, and &#x003b2;&#x02010;Actin as loading control. (E) Cell viability assay of MDA&#x02010;MB&#x02010;231 and MCF&#x02010;7 cells treated with 25 or 50&#x02009;&#x003bc;<sc>m</sc> entacapone or DMSO control for 3&#x02009;days. Values are shown as mean (&#x02212;) and individual data points (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3); significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (F) Transwell migration assay at 48&#x02009;h of MDA&#x02010;MB&#x02010;231 cells treated with 25&#x02009;&#x003bc;<sc>m</sc> entacapone or DMSO. Scale bar represents 500&#x02009;&#x003bc;m. Quantification is shown at the right as mean (&#x02212;) and individual data points (<italic toggle="yes">n</italic>&#x02009;=&#x02009;6); significance determined by Student's <italic toggle="yes">t</italic>&#x02010;test. **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates).</p></caption><graphic xlink:href="FEBS-292-2688-g011" position="anchor" id="jats-graphic-5"/></fig><fig position="float" fig-type="Fig." id="febs70033-fig-0003"><label>Fig. 3</label><caption><p>FTO knockdown impairs cell proliferation and migration in untransformed MCF10A cells. (A) A representative immunoblot showing FTO expression levels in MCF10A cells with FTO knockdown (shFTO1 or shFTO2) or in scrambled&#x02010;shRNA control cells (scr) (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 technical replicates). The immunoblot showing &#x003b2;&#x02010;Actin expression was used as loading control. (B) Cell viability assay of MCF10A cells with FTO knockdown (shFTO1 or shFTO2) or scrambled control (scr) after cultivation for 3&#x02009;days. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4) biological replicates. (C) Transwell migration assay of MCF10A cells with FTO knockdown (shFTO1 or shFTO2) or scrambled control (scr) at 48&#x02009;h. Scale bar represents 500&#x02009;&#x003bc;m. Quantification is shown at the right. Significance determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.0001 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4 biological replicates).</p></caption><graphic xlink:href="FEBS-292-2688-g006" position="anchor" id="jats-graphic-7"/></fig></sec><sec id="febs70033-sec-0004"><title>
<styled-content style="fixed-case" toggle="no">FTO</styled-content> regulates <styled-content style="fixed-case" toggle="no">ECM</styled-content> and <styled-content style="fixed-case" toggle="no">EMT</styled-content> gene expression</title><p>Since FTO was shown to regulate mRNA&#x02010;stability we examined FTO knockdown&#x02010;induced alterations in the genome&#x02010;wide transcriptome. Transcriptome analysis of MDA&#x02010;MB&#x02010;231 cells identified 228 up&#x02010; and 525 downregulated genes upon FTO knockdown (FDR&#x02009;&#x0003c;0.05, fold change &#x0003e;1.5) (Fig.&#x000a0;<xref rid="febs70033-fig-0004" ref-type="fig">4A</xref>; Table&#x000a0;<xref rid="febs70033-supitem-0001" ref-type="supplementary-material">S1</xref>). The finding that more genes were downregulated than upregulated agrees with the described mRNA destabilizing effect of m6A modification [<xref rid="febs70033-bib-0009" ref-type="bibr">9</xref>]. Gene Set Enrichment Analysis (GSEA) (<ext-link xlink:href="https://www.gsea-msigdb.org/gsea" ext-link-type="uri">https://www.gsea&#x02010;msigdb.org/gsea</ext-link>, Broad Institute) [<xref rid="febs70033-bib-0036" ref-type="bibr">36</xref>] revealed a significant negative enrichment of the epithelial to mesenchymal transition (EMT) signature in FTO knockdown cells compared to control cells (Fig.&#x000a0;<xref rid="febs70033-fig-0004" ref-type="fig">4B</xref>). Furthermore, most of the top 15 significantly enriched gene ontology (GO) terms from the downregulated genes are related to the extracellular matrix (ECM) or EMT (Fig.&#x000a0;<xref rid="febs70033-fig-0004" ref-type="fig">4C</xref>). qPCR analysis confirmed the downregulation of a subset of genes by FTO knockdown, including Collagen Type XII Alpha 1 Chain (<italic toggle="yes">COL12A1</italic>), Fibronectin 1 (<italic toggle="yes">FN1</italic>), Matrix Metalloproteinase 1 (<italic toggle="yes">MMP1</italic>), Leucine Rich Repeat Containing 15 (<italic toggle="yes">LRRC15</italic>) and Tenascin C (<italic toggle="yes">TNC</italic>) (Fig.&#x000a0;<xref rid="febs70033-fig-0004" ref-type="fig">4D</xref>). Moreover, in MDA&#x02010;MB&#x02010;231 cells with FTO knockdown, the reintroduction of FTO led to a notable increase in the expression of the aforementioned genes. However, statistical significance was only reached for LRRC15 among these genes (Fig.&#x000a0;<xref rid="febs70033-fig-0004" ref-type="fig">4E</xref>). Overall, the results concur with the rescue of the Transwell migration phenotype upon FTO re&#x02010;expression in FTO&#x02010;knockdown MDA&#x02010;MB&#x02010;231 cells (Fig.&#x000a0;<xref rid="febs70033-fig-0004" ref-type="fig">4D</xref>).</p><fig position="float" fig-type="Fig." id="febs70033-fig-0004"><label>Fig. 4</label><caption><p>Transcriptome analysis revealing FTO&#x02010;regulated extracellular matrix (ECM) and epithelial&#x02010;mesenchymal transition (EMT) genes. (A) Transcriptome analysis of MDA&#x02010;MB&#x02010;231 cells with FTO knockdown versus scrambled&#x02010;shRNA (scr) control (<italic toggle="yes">n</italic>&#x02009;=&#x02009;2 biological replicates). Significantly regulated genes are displayed in either red (downregulated) or green (upregulated)(fold change &#x0003e;1.5; FDR&#x02009;&#x0003c;0.05). (B) Gene set enrichment analysis (GSEA) for the hallmark epithelial&#x02010;mesenchymal transition shows significant negative enrichment in MDA&#x02010;MB&#x02010;231 FTO knockdown cells versus scrambled&#x02010;shRNA (scr) control. (C) Gene ontology (GO) term analysis of biological processes downregulated upon FTO knockdown in MDA&#x02010;MB&#x02010;231 cells versus scrambled&#x02010;shRNA control. Significantly enriched GO&#x02010;terms (<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001) are shown with their respective <italic toggle="yes">P</italic>&#x02010;values (Fisher elim. topGO). (D) RT&#x02010;qPCR analysis of ECM/EMT&#x02010;related genes found to be downregulated upon FTO knockdown (shFTO1 or shFTO2) versus shRNA&#x02010;scrambled (scr) control in MDA&#x02010;MB&#x02010;231 cells. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (mean&#x02009;&#x000b1;&#x02009;SD, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (E) RT&#x02010;qPCR analysis of ECM/EMT&#x02010;related genes in MDA&#x02010;MB&#x02010;231 FTO knockdown (shFTO1) cells after re&#x02010;expression of FTO compared to empty vector (EV) control. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01 (mean&#x02009;&#x000b1;&#x02009;SD, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates).</p></caption><graphic xlink:href="FEBS-292-2688-g001" position="anchor" id="jats-graphic-9"/></fig><p>Others have screened cell signaling components for their effect on TNBC cell migration [<xref rid="febs70033-bib-0037" ref-type="bibr">37</xref>]. Out of 4198 individual genes, 153 were identified and validated to regulate cell migration in MDA&#x02010;MB&#x02010;231 cells [<xref rid="febs70033-bib-0037" ref-type="bibr">37</xref>]. We overlaid our list of downregulated genes with the validated hits from [<xref rid="febs70033-bib-0037" ref-type="bibr">37</xref>] and identified Low Density Lipoprotein Receptor&#x02010;Related Protein 1 (<italic toggle="yes">LRP1</italic>), cAMP Responsive Element Binding Protein 5 (<italic toggle="yes">CREB5</italic>) and SWI/SNF related, matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily D, Member 3 (<italic toggle="yes">SMARCD3</italic>) as the only three shared regulated genes. Upon FTO knockdown or treatment with entacapone we observed a significant and consistent downregulation only for <italic toggle="yes">SMARCD3</italic> in MDA&#x02010;MB&#x02010;231 cells (Fig.&#x000a0;<xref rid="febs70033-fig-0005" ref-type="fig">5A</xref>). In another study, pro&#x02010;apoptotic BCL2 interacting protein 3 (BNIP3) was identified as the main gene that is downregulated by FTO through m6A demethylation. However, we failed to observe upregulation of BNIP3 in response to FTO knockdown in MDA&#x02010;MB&#x02010;231 cells and rather observed a trend toward downregulation of BNIP3 (Fig.&#x000a0;<xref rid="febs70033-fig-0005" ref-type="fig">5B</xref>).</p><fig position="float" fig-type="Fig." id="febs70033-fig-0005"><label>Fig. 5</label><caption><p>Analysis of specific genes regulation by FTO knockdown or inhibition of FTO. (A) Left graph, RT&#x02010;qPCR analysis of <italic toggle="yes">LRP1</italic>, <italic toggle="yes">SMARCD3</italic> and <italic toggle="yes">CREB5</italic> expression in MDA&#x02010;MB&#x02010;231 cells upon FTO knockdown (shFTO1 or shFTO2) versus shRNA&#x02010;scrambled (scr) control. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01 (mean&#x02009;&#x000b1;&#x02009;SD, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). Right graph, RT&#x02010;qPCR analysis of <italic toggle="yes">LRP1</italic>, <italic toggle="yes">SMARCD3</italic> and <italic toggle="yes">CREB5</italic> expression in MDA&#x02010;MB&#x02010;231 cells treated with 25 or 50&#x02009;&#x003bc;<sc>m</sc> entacapone or DMSO for 3&#x02009;days. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (mean&#x02009;&#x000b1;&#x02009;SD, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (B) RT&#x02010;qPCR analysis of <italic toggle="yes">BNIP3</italic> expression in MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1 or shFTO2) versus shRNA&#x02010;scrambled (scr) control. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (mean&#x02009;&#x000b1;&#x02009;SD, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates).</p></caption><graphic xlink:href="FEBS-292-2688-g007" position="anchor" id="jats-graphic-11"/></fig></sec><sec id="febs70033-sec-0005"><title>
<styled-content style="fixed-case" toggle="no">FTO</styled-content> does not directly regulate <styled-content style="fixed-case" toggle="no">ECM</styled-content>/<styled-content style="fixed-case" toggle="no">EMT mRNA</styled-content> stability</title><p>m6A&#x02010;modification of mRNAs is linked to the regulation of mRNA stability by promoting degradation [<xref rid="febs70033-bib-0009" ref-type="bibr">9</xref>, <xref rid="febs70033-bib-0014" ref-type="bibr">14</xref>]. To examine whether the downregulation of ECM and EMT mRNAs in response to FTO knockdown is caused by mRNA degradation, we treated the cells with the transcription inhibitor actinomycin D and followed the degradation of selected transcripts over time. As expected, FTO mRNA levels declined in FTO&#x02010;knockdown cells (Fig.&#x000a0;<xref rid="febs70033-fig-0006" ref-type="fig">6A</xref>). However, none of the regulated transcripts showed changes in mRNA stability upon FTO knockdown (Fig.&#x000a0;<xref rid="febs70033-fig-0006" ref-type="fig">6B</xref>). In addition, we did not observe an increase in mRNA&#x02010;m6A levels for any of the regulated genes analyzed by methylated&#x02010;RNA immunoprecipitation using a m6A antibody followed by real&#x02010;time reverse transcription polymerase chain reaction (MeRIP&#x02010;RT&#x02010;qPCR) (Fig.&#x000a0;<xref rid="febs70033-fig-0006" ref-type="fig">6C</xref>). These data indicate that FTO does not regulate these transcripts directly.</p><fig position="float" fig-type="Fig." id="febs70033-fig-0006"><label>Fig. 6</label><caption><p>FTO does not regulate ECM/EMT target gene transcript stability or level of m6A modification. (A) Decay curves of FTO mRNA in MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1) versus scrambled&#x02010;shRNA (scr) control. Significance was determined by multiple Student's <italic toggle="yes">t</italic>&#x02010;test with Holm&#x02010;Sidak correction, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (mean&#x02009;&#x000b1;&#x02009;SEM, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (B) Decay curves of mRNA from indicated genes in MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1) versus scrambled (scr) control. Significance was determined by multiple Student's <italic toggle="yes">t</italic>&#x02010;test with Holm&#x02010;Sidak correction (mean&#x02009;&#x000b1;&#x02009;SEM, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (C) Quantification of mRNA&#x02010;m6A levels of indicated genes in MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1 or shFTO2) versus scrambled (scr) control by MeRIP&#x02010;qPCR. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test.*<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01. n.d.: not detected (mean&#x02009;&#x000b1;&#x02009;SEM, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates).</p></caption><graphic xlink:href="FEBS-292-2688-g008" position="anchor" id="jats-graphic-13"/></fig></sec><sec id="febs70033-sec-0006"><title>
<styled-content style="fixed-case" toggle="no">FTO</styled-content> deficiency does not significantly affect translation in <styled-content style="fixed-case" toggle="no">TNBC</styled-content> cells</title><p>In addition to mRNA turnover, FTO function has been linked to the regulation of mRNA&#x02010;translation [<xref rid="febs70033-bib-0010" ref-type="bibr">10</xref>, <xref rid="febs70033-bib-0012" ref-type="bibr">12</xref>]. To investigate FTO&#x02010;dependent differences in the translatome, we performed ribosome profiling experiments with FTO knockdown and scrambled&#x02010;shRNA MDA&#x02010;MB&#x02010;231 TNBC cells. To our surprise, the translatome was only mildly affected by FTO deficiency and only five transcripts showed more than twofold and significantly altered translation efficiencies (FDR&#x02009;&#x0003c;0.05, fold change &#x0003e;2, Fig.&#x000a0;<xref rid="febs70033-fig-0007" ref-type="fig">7A</xref>; Table&#x000a0;<xref rid="febs70033-supitem-0001" ref-type="supplementary-material">S2</xref>). The most strongly reduced in ribosome loading was DICER1, yet DICER mRNA levels determined by RT&#x02010;qPCR or DICER protein levels analyzed by immunoblotting did not reveal a significant change upon FTO knockdown (Fig.&#x000a0;<xref rid="febs70033-fig-0007" ref-type="fig">7B,C,E</xref>). The SMAD6 and COL1A1 transcripts showed mildly reduced ribosome loading. RT&#x02010;qPCR analysis showed no significant difference in expression levels (Fig.&#x000a0;<xref rid="febs70033-fig-0007" ref-type="fig">7D</xref>). Protein levels of COL1A1 were found reduced after long&#x02010;term (20&#x02009;days posttransduction) culture of FTO&#x02010;knockdown cells and protein levels of SMAD6 were found lower only for the most effective shRNA1&#x02010;FTO knockdown (Fig.&#x000a0;<xref rid="febs70033-fig-0007" ref-type="fig">7E</xref>). These analyses suggest that FTO&#x02010;mediated demethylation of the COL1A1 and SMAD6 mRNAs enhances their translation, of which FTO&#x02010;COL1A1 regulation has also been observed by others [<xref rid="febs70033-bib-0038" ref-type="bibr">38</xref>].</p><fig position="float" fig-type="Fig." id="febs70033-fig-0007"><label>Fig. 7</label><caption><p>FTO knockdown has a limited effect on mRNA translation. (A) Fold change in translation efficiency upon FTO knockdown in MDA&#x02010;MB&#x02010;231 cells is displayed, color coded by FDR. Significantly regulated genes above threshold are indicated by gene symbol. (B) RT&#x02010;qPCR analysis of <italic toggle="yes">DICER</italic> mRNA expression in MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1 or shFTO2) versus shRNA&#x02010;scrambled (scr) control. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test (mean&#x02009;&#x000b1;&#x02009;SEM, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (C) Immunoblots showing no change in DICER protein expression upon knockdown of FTO (shFTO1 or shFTO2) in MDA&#x02010;MB&#x02010;231 versus scrambled control (SCR). &#x003b2;&#x02010;Actin was used as loading control. Quantification is shown on the right. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test (mean&#x02009;&#x000b1;&#x02009;SEM, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (D) RT&#x02010;qPCR analysis of <italic toggle="yes">COL1A1</italic> and <italic toggle="yes">SMAD6</italic> mRNA expression in MDA&#x02010;MB&#x02010;231 upon FTO knockdown (shFTO1 or shFTO2) versus shRNA&#x02010;scrambled (scr) control. Significance was determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test (mean&#x02009;&#x000b1;&#x02009;SD, <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (E) Immunoblot analysis of COL1A1, SMAD6, and DICER protein expression in MDA&#x02010;MB&#x02010;231 upon FTO knockdown (shFTO1 or shFTO2) versus shRNA&#x02010;scrambled (scr) control, and &#x003b2;&#x02010;Actin as loading control. 5&#x02009;days and 20&#x02009;days refer to days in cell culture after transduction with shRNA retroviral vector. (F) Subsequence abundance analysis of codons at the +15 position relative to the ribosome protected fragment (RPF) 5&#x02032;&#x02010;end. All transcripts in the coding frame are considered for this analysis. No significant enrichment or depletion of codons can be seen, indicating no obvious shortages of amino acids causing ribosome stalls/halts.</p></caption><graphic xlink:href="FEBS-292-2688-g009" position="anchor" id="jats-graphic-15"/></fig><p>The ribosome profiling experiment provides additional data about possible FTO&#x02010;related amino acid or tRNA metabolism. The position of a ribosome on the mRNA&#x02010;ribosome protected fragment (RPF) can be deduced from the RPF 5&#x02032; end. Using this information and the known mRNA reading frame, the codons in the ribosomal A (aminoacyl), P (peptidyl&#x02010;transfer) and E (exit) sites can be determined. Positions 9, 12 and 15 from the 5&#x02032; end of the RFPs correspond to respectively the ribosomal E, P and A site, respectively. When for example a particular amino acid or tRNA is depleted from cells, this will cause an accumulation of ribosomes on the corresponding codons. Since amino acid recognition takes place at the A&#x02010;site, the affected codons will be enriched at position 15 in RPFs [<xref rid="febs70033-bib-0039" ref-type="bibr">39</xref>]. Using differential ribosome codon reading (diricore) analysis [<xref rid="febs70033-bib-0039" ref-type="bibr">39</xref>] no significant differences in ribosome A&#x02010;site occupancy were observed (Fig.&#x000a0;<xref rid="febs70033-fig-0007" ref-type="fig">7F</xref>). As no specific amino acid or tRNA shortages are induced by FTO deficiency, this indicates that FTO is not critically involved in their metabolic regulation.</p></sec><sec id="febs70033-sec-0007"><title>
<styled-content style="fixed-case" toggle="no">FTO</styled-content> and <styled-content style="fixed-case" toggle="no">WTAP</styled-content> regulate C/<styled-content style="fixed-case" toggle="no">EBP&#x003b2;</styled-content> isoform expression</title><p>Although transcript levels of genes associated with ECM/EMT were reduced upon FTO knockdown in MDA&#x02010;MB&#x02010;231 cells, this effect seems to be not directly mediated by FTO since FTO knockdown neither reduced the ribosome occupancy nor the stability of the transcripts. We therefore reasoned that their regulation likely occurs at the transcriptional level through a factor that is controlled by FTO. Additionally, the unexpectedly low number of genes exhibiting more than a twofold translational regulation prompted the question of whether FTO might influence specific translation events on individual mRNAs without significantly altering overall ribosome loading. The regulation and functions of the transcription factor of C/EBP&#x003b2; fits in this scenario, as it undergoes distinct translation into three protein isoforms and these isoforms play a pivotal role in regulating ECM/EMT genes [<xref rid="febs70033-bib-0040" ref-type="bibr">40</xref>]. In addition to C/EBP&#x003b2;&#x02010;LAP1 and &#x02010;LAP2 protein isoforms that are generated by regular translation, translation into an additional N&#x02010;terminally truncated C/EBP&#x003b2;&#x02010;LIP isoform involves a <italic toggle="yes">cis</italic>&#x02010;regulatory upstream open reading frame (uORF) in the transcript leader sequence (Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8A</xref>) [<xref rid="febs70033-bib-0031" ref-type="bibr">31</xref>]. We have shown previously that its translational upregulation supports breast cancer cell proliferation and migration and&#x000a0;regulates the expression of ECM/EMT transcripts&#x000a0;[<xref rid="febs70033-bib-0040" ref-type="bibr">40</xref>]. Sequence&#x02010;based RNA adenosine methylation site predictor (SRAMP, <ext-link xlink:href="http://www.cuilab.cn/sramp" ext-link-type="uri">http://www.cuilab.cn/sramp</ext-link>) identified six putative m6A sites with the highest confidence level in the CEBPB mRNA [<xref rid="febs70033-bib-0041" ref-type="bibr">41</xref>]. Published data on m6A individual&#x02010;nucleotide&#x02010;resolution crosslinking and immunoprecipitation (miCLIP) experiments confirmed m6A modification of four of these sites [<xref rid="febs70033-bib-0042" ref-type="bibr">42</xref>], while antibody&#x02010;free deamination adjacent to RNA modification targets (DART)&#x02010;seq identified two additional sites [<xref rid="febs70033-bib-0043" ref-type="bibr">43</xref>]. In concordance with the genome&#x02010;wide distribution of m6A on transcripts&#x000a0;[<xref rid="febs70033-bib-0006" ref-type="bibr">6</xref>], all but one of these sites are in the 3&#x02032;UTR of the CEBPB mRNA (Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8A</xref>). In a study using m<sup>6</sup>A&#x02010;level and isoform&#x02010;characterization sequencing (m<sup>6</sup>A&#x02010;LAIC&#x02010;seq), CEBPB mRNA was found to be m6A&#x02010;modified in a human embryonic stem cell or B&#x02010;cell lymphoblastoid cell line [<xref rid="febs70033-bib-0044" ref-type="bibr">44</xref>]. To study whether m6A modification of the CEBPB mRNA contributes to its translational regulation, we applied FTO knockdown (shFTO) in triple&#x02010;negative MDA&#x02010;MB&#x02010;231 and luminal A&#x02010;type MCF&#x02010;7 breast cancer cell lines, and mouse embryonic fibroblasts (MEFs). Knockdown of FTO decreased C/EBP&#x003b2;&#x02010;LIP levels with a concomitant decrease in the&#x000a0;C/EBP&#x003b2;&#x02010;LIP/LAP ratio in MDA&#x02010;MB&#x02010;231 cells (Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8B</xref>) and MCF&#x02010;7 cells (Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8C</xref>), and to a lesser extent in MEFs (Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8D</xref>). At least in MDA&#x02010;MB&#x02010;231 cells, FTO knockdown did not affect CEBPB mRNA stability (Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8E</xref>). Subsequently, we investigated the effects of abolishing methyltransferase activity, which catalyzes m6A modification, by targeting the methyltransferase complex component, WTAP. Knockdown of WTAP in MDA&#x02010;MB&#x02010;231 cells resulted in elevated expression levels of C/EBP&#x003b2;&#x02010;LIP (Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8F</xref>). To directly examine FTO&#x02010;related changes in CEBPB mRNA&#x02010;m6A levels, we performed methylated RNA immunoprecipitation using a m6A antibody followed by real&#x02010;time reverse transcription polymerase chain reaction (MeRIP&#x02010;RT&#x02010;qPCR). Recovery after IP over input was determined as a reflection of transcript m6A levels. A clear trend toward increased CEBPB mRNA m6A&#x02010;levels upon FTO knockdown was observed that did not reach statistical significance because of high experimental variation (Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8G</xref>).</p><fig position="float" fig-type="Fig." id="febs70033-fig-0008"><label>Fig. 8</label><caption><p>FTO or WTAP knockdown reciprocally regulates C/EBP&#x003b2; isoform expression. (A) Schematic overview of the human CEBPB mRNA with indicated translation start sites for LAP1, LAP2, LIP and the uORF. Predicted (SRAMP [<xref rid="febs70033-bib-0041" ref-type="bibr">41</xref>]) and experimentally detected m6A modifications from HEK293T&#x000a0;cells (miCLIP: Linder <italic toggle="yes">et&#x000a0;al</italic>. 2015 [<xref rid="febs70033-bib-0042" ref-type="bibr">42</xref>], DARTseq Meyer 2019 [<xref rid="febs70033-bib-0043" ref-type="bibr">43</xref>]) are indicated with adenosine base number. (B) Immunoblot showing reduced levels of C/EBP&#x003b2;&#x02010;LIP upon knockdown of FTO (shFTO1 or shFTO2) in MDA&#x02010;MB&#x02010;231 cells versus scrambled control (scr). &#x003b2;&#x02010;Actin was used as loading control. Quantification of C/EBP&#x003b2;&#x02010;LIP/LAP ratio with significance determined by Student's <italic toggle="yes">t</italic>&#x02010;test. *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (C) Immunoblot showing reduced levels of C/EBP&#x003b2;&#x02010;LIP upon knockdown of FTO (shFTO1 or shFTO2) in MCF&#x02010;7 cells versus scrambled control (scr). &#x003b2;&#x02010;Actin was used as loading control. Quantification of C/EBP&#x003b2;&#x02010;LIP/LAP ratio with significance determined by Student's <italic toggle="yes">t</italic>&#x02010;test. **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4 biological replicates). (D) Immunoblot showing reduced levels of C/EBP&#x003b2;&#x02010;LIP upon knockdown of FTO (shFTO1) in MEF cells versus scrambled control (SCR). &#x003b2;&#x02010;Actin was used as loading control. Quantification of C/EBP&#x003b2;&#x02010;LIP/LAP ratio with significance determined by Student's <italic toggle="yes">t</italic>&#x02010;test. *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (E) Decay curves of CEBPB mRNA from MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1) versus shRNA&#x02010;scrambled (scr) control. Values represent mean&#x02009;&#x000b1;&#x02009;SEM of 3 biological replicates. Significance was determined by multiple Student's <italic toggle="yes">t</italic>&#x02010;test with Holm&#x02010;Sidak correction. (F) Immunoblot showing increased levels of C/EBP&#x003b2;&#x02010;LIP upon knockdown of WTAP (shWTAP) in MDA&#x02010;MB&#x02010;231 cells versus scrambled control (scr). &#x003b2;&#x02010;Actin was used as loading control. Quantification of C/EBP&#x003b2;&#x02010;LIP/LAP ratio with significance determined by Student's <italic toggle="yes">t</italic>&#x02010;test. **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (G) Quantification of mRNA&#x02010;m6A levels for <italic toggle="yes">CEBPB</italic> and <italic toggle="yes">HPRT</italic> (control gene not regulated by m6A) in MDA&#x02010;MB&#x02010;231 cells upon knockdown of FTO (shFTO1 or shFTO2) versus scrambled control (scr) by MeRIP&#x02010;RT&#x02010;qPCR. Bars represent mean&#x02009;&#x000b1;&#x02009;SEM (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 biological replicates). (H) Immunoblot showing loss of FTO expression in three independent FTO knockout clones obtained by CRISPR&#x02010;Cas9 targeting compared to parental MDA&#x02010;MB&#x02010;231 cells. &#x003b2;&#x02010;Actin was used as loading control.</p></caption><graphic xlink:href="FEBS-292-2688-g005" position="anchor" id="jats-graphic-17"/></fig><p>To investigate whether FTO interacts with CEBPB mRNA, we conducted an FTO&#x02010;specific RNA immunoprecipitation (RIP). We generated MDA&#x02010;MB&#x02010;231 cells which an FTO knockout using CRISPR/Cas9 gene editing (clone 2, Fig.&#x000a0;<xref rid="febs70033-fig-0008" ref-type="fig">8H</xref>). In these cells, we ectopically expressed human FTO fused to a 3xFLAG tag at its N&#x02010;terminus (3xFLAG&#x02010;FTO) or the 3xFLAG tag alone as a control. Additionally, HPRT mRNA, which is known not to be acetylated, was measured as a negative control. Following FLAG&#x02010;specific immunoprecipitation, we assessed the binding of CEBPB or HPRT mRNA to 3xFLAG&#x02010;FTO compared to the 3xFTO control (Fig.&#x000a0;<xref rid="febs70033-fig-0009" ref-type="fig">9A,B</xref>). As shown in Fig.&#x000a0;<xref rid="febs70033-fig-0009" ref-type="fig">9B</xref>, CEBPB mRNA was significantly enriched in 3xFLAG&#x02010;FTO immunoprecipitation relative to the 3xFLAG control, demonstrating that FTO binds to CEBPB mRNA. In contrast, no differential binding was observed for HPRT.</p><fig position="float" fig-type="Fig." id="febs70033-fig-0009"><label>Fig. 9</label><caption><p>FTO binds the CEBPB mRNA. (A) Immunoblot with a FLAG&#x02010;specific antibody showing immunoprecipitated 3xFLAG&#x02010;FTO and 3xFLAG control peptide after FLAG&#x02010;specific immunoprecipitation as well as in input control samples as indicated (3xFLAG control peptide is fusion to a random sequence derived from the expression vector). Immunoprecipitation of 3xFLAG&#x02010;FTO was confirmed with an FTO&#x02010;specific antibody. A &#x003b2;&#x02010;Actin antibody served as loading control for the input samples. The experiment was performed once (<italic toggle="yes">n</italic>&#x02009;=&#x02009;1). (B) <italic toggle="yes">CEBPB</italic> mRNA (left) or <italic toggle="yes">HPRT</italic> mRNA (right, negative control) enrichment in 3xFLAG&#x02010;FTO cells and in 3xFLAG control cells presented as IP/input and normalized to empty vector control cells. Significance determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, ns, not significant, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01, (<italic toggle="yes">n</italic>&#x02009;=&#x02009;3 technical replicates).</p></caption><graphic xlink:href="FEBS-292-2688-g002" position="anchor" id="jats-graphic-19"/></fig><p>Taken together, the data suggest that reversible WTAP&#x02010; and FTO&#x02010;controlled m6A modification of CEBPB mRNA alters its translation.</p></sec><sec id="febs70033-sec-0008"><title>C/<styled-content style="fixed-case" toggle="no">EBP&#x003b2;</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">LIP</styled-content> overexpression partially rescues the migration phenotype of cells with <styled-content style="fixed-case" toggle="no">FTO</styled-content> knockdown</title><p>Since we showed earlier that LIP stimulates the migration of breast cancer as well as untransformed breast epithelial cells [<xref rid="febs70033-bib-0040" ref-type="bibr">40</xref>], we investigated whether overexpression of C/EBP&#x003b2;&#x02010;LIP would reverse the reduced MDA&#x02010;MB&#x02010;231 cell migration phenotype caused by FTO knockdown. Overexpression of C/EBP&#x003b2;&#x02010;LIP in wt MDA&#x02010;MB&#x02010;231 control cells significantly further increased cell migration (Boyden chamber) in one of the two independent experiments (Fig.&#x000a0;<xref rid="febs70033-fig-0010" ref-type="fig">10A&#x02013;D</xref>). FTO knockdown strongly reduced cell migration in all cases, as expected. C/EBP&#x003b2;&#x02010;LIP overexpression efficiently rescued cell migration in shFTO2&#x02010;knockout cells and moderately rescued migration in one of the shFTO1&#x02010;knockout cells. Altogether, the data indicate that (m6A)&#x02010;demethylation of CEBPB mRNA facilitates C/EBP&#x003b2;&#x02010;LIP upregulation, which could contribute to the promigratory phenotype induced by FTO.</p><fig position="float" fig-type="Fig." id="febs70033-fig-0010"><label>Fig. 10</label><caption><p>Ectopic expression of C/EBP&#x003b2;&#x02010;LIP enhances cell migration independent of FTO (<italic toggle="yes">n</italic>&#x02009;=&#x02009;2 biological replicates). (A) First Transwell migration assay of MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1 or shFTO2) or scrambled control (scr) with overexpression C/EBP&#x003b2;&#x02010;LIP or empty vector (EV) control, at 48&#x02009;h. The graph shows quantification of migrated cells with pictures of stained cells presented on the right. Scale bar represents 500&#x02009;&#x003bc;m. Significance determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4 technical replicates). (B) Immunoblot showing overexpression of C/EBP&#x003b2;&#x02010;LIP in FTO knockdown (shFTO1 or shFTO2) or scrambled&#x02010;shRNA (scr) control MDA&#x02010;MB&#x02010;231 cells. &#x003b2;&#x02010;Actin was used as loading control. (C) Second Transwell migration assay of MDA&#x02010;MB&#x02010;231 cells with FTO knockdown (shFTO1 or shFTO2) or scrambled control (scr) with overexpression C/EBP&#x003b2;&#x02010;LIP or empty vector (EV) control, at 48&#x02009;h. The graph shows quantification of migrated cells with pictures of stained cells presented on the right. Scale bar represents 500&#x02009;&#x003bc;m. Significance determined by one&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test, *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01 (<italic toggle="yes">n</italic>&#x02009;=&#x02009;4 technical replicates). (D) Immunoblot showing overexpression of C/EBP&#x003b2;&#x02010;LIP in FTO&#x02010;knockdown (shFTO1 or shFTO2) or scrambled&#x02010;shRNA (scr) control MDA&#x02010;MB&#x02010;231 cells. &#x003b2;&#x02010;Actin was used as loading control.</p></caption><graphic xlink:href="FEBS-292-2688-g010" position="anchor" id="jats-graphic-21"/></fig></sec></sec><sec sec-type="discussion" id="febs70033-sec-0009"><title>Discussion</title><p>Here we present data showing that FTO expression stimulates the proliferation and migration of MDA&#x02010;MB&#x02010;231 (triple&#x02010;negative breast cancer) and MCF&#x02010;7 (luminal A type metastatic adenocarcinoma) breast cancer cells in cell culture. Our ribosome profiling experiment and transcriptome analysis using MDA&#x02010;MB&#x02010;231 cells and FTO knockdown showed little effect on the translatome but revealed significant regulation of transcripts involved in the ECM and EMT. In addition, the data show that FTO knockdown reduces the expression of C/EBP&#x003b2;&#x02010;LIP, while WTAP knockdown results in higher levels of C/EBP&#x003b2;&#x02010;LIP, suggesting that binding of FTO to CEBPB mRNA and FTO&#x02010;mediated m6A demethylation is involved in the regulated translation of the CEBPB mRNA into its protein isoforms C/EBP&#x003b2;&#x02010;LAP1/2 and C/EBP&#x003b2;&#x02010;LIP.</p><p>Various roles of FTO&#x02010;mediated m6A demethylation in the development of cancer progression has emerged in recent years. While tumor suppressive functions for FTO have been described in for example colorectal cancer and hepatocellular carcinoma, reports describing oncogenic functions in different cancer types including lung cancer, glioma and AML are far more abundant (reviewed in [<xref rid="febs70033-bib-0020" ref-type="bibr">20</xref>]). Analysis of broad collections of TNBC cells and samples suggests that FTO function must be maintained for TNBC cell survival. The catalog of somatic mutations in cancer (COSMIC, <ext-link xlink:href="https://cancer.sanger.ac.uk/cosmic" ext-link-type="uri">https://cancer.sanger.ac.uk/cosmic</ext-link>) database reports only a single intronic mutation in the FTO gene in 117 TNBC samples analyzed. Furthermore, in the 83 breast cancer cell lines listed in the cancer cell line encyclopedia (CCLE) dependency map portal (depmap, <ext-link xlink:href="https://depmap.org/portal/" ext-link-type="uri">https://depmap.org/portal/</ext-link>) only a single cell line with an intronic mutation was found.</p><p>Our results and data presented by Niu <italic toggle="yes">et&#x000a0;al</italic> [<xref rid="febs70033-bib-0023" ref-type="bibr">23</xref>] show that FTO function is required for breast cancer cell proliferation and migration. The study by Niu <italic toggle="yes">et&#x000a0;al</italic>. [<xref rid="febs70033-bib-0023" ref-type="bibr">23</xref>] showed that FTO is upregulated in breast tumor samples together with downregulation of METTL3/14, ALKBH5, YTHDC2, and YTHDF1, and is associated with an overall decline in global mRNA m6A levels. Furthermore, they showed that in breast cancer patients high FTO levels correlate with poorer survival. Niu <italic toggle="yes">et&#x000a0;al</italic>. [<xref rid="febs70033-bib-0023" ref-type="bibr">23</xref>] identified the pro&#x02010;apoptotic BNIP3 as the downstream target of FTO by transcriptome and m6A&#x02010;seq analysis using MDA&#x02010;MB&#x02010;231 FTO&#x02010;knockdown and MCF&#x02010;7 cells treated with the FTO inhibitor <ext-link xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3188" ext-link-type="uri">GSE3188</ext-link>. They also showed that BNIP3 expression alleviates FTO&#x02010;dependent tumor growth in a xenograft mouse model. However, we did not observe such regulation of BNIP3 in MDA&#x02010;MB&#x02010;231 cells and rather observed downregulation upon FTO knockdown.</p><p>Instead, our study shows that FTO knockdown inhibits and WTAP knockdown stimulates translation into C/EBP&#x003b2;&#x02010;LIP, which can act as an oncogene and regulates EMT/ECM genes in TNBC [<xref rid="febs70033-bib-0040" ref-type="bibr">40</xref>]. This suggests that for efficient uORF&#x02010;dependent regulation of LIP, FTO&#x02010;mediated CEBPB mRNA demethylation is required, which is supported by the results of our MeRIP&#x02010;RT&#x02010;qPCR and FTO&#x02010;specific RNA&#x02010;immunoprecipitation experiments shown in Fig.&#x000a0;<xref rid="febs70033-fig-0005" ref-type="fig">5E&#x02013;G</xref>, respectively. Published data and bioinformatic analysis identified several m6A sites in the CEBPB mRNA (Fig.&#x000a0;<xref rid="febs70033-fig-0005" ref-type="fig">5A</xref>) [<xref rid="febs70033-bib-0041" ref-type="bibr">41</xref>, <xref rid="febs70033-bib-0042" ref-type="bibr">42</xref>, <xref rid="febs70033-bib-0043" ref-type="bibr">43</xref>] and future studies should aim to identify the m6A site(s) and involved translational mechanisms in FTO&#x02010;C/EBP&#x003b2; regulation. In addition to m6A sites, FTO also demethylates m6Am site that are located adjacent to the mRNA 7&#x02010;methylguanosine cap [<xref rid="febs70033-bib-0020" ref-type="bibr">20</xref>, <xref rid="febs70033-bib-0045" ref-type="bibr">45</xref>], which raises the question whether the regulation of CEBPB mRNA translation may involve an m6Am site. However, this is rather unlikely because previous m6Am&#x02010;seq experiments conducted by others did not detect an m6Am site in the CEBPB mRNA sequence&#x000a0;[<xref rid="febs70033-bib-0046" ref-type="bibr">46</xref>].</p><p>We show that ectopic expression of C/EBP&#x003b2;&#x02010;LIP stimulates cell migration in FTO knockdown cells, suggesting that at least part of the effects of FTO on cell migration occur through regulation of C/EBP&#x003b2;&#x02010;LIP. The question that arises from this observation is whether FTO collectively regulates mRNAs containing uORFs or other translation <italic toggle="yes">cis</italic>&#x02010;regulatory elements. In line with this hypothesis, amino acid starvation was shown to regulate the translation activating transcription factor 4 (ATF4) via m6A [<xref rid="febs70033-bib-0047" ref-type="bibr">47</xref>]. ATF4 translation depends on reinitiation following uORF translation, allowing bypassing of an inhibitory second uORF when eIF2&#x02010;GTP levels are low [<xref rid="febs70033-bib-0048" ref-type="bibr">48</xref>]. FTO or ALKBH5 knockdown represses ATF4 reinitiation, whereas knocking down the m(6)A methyltransferase subunits METTL3 or METTL14 promotes ATF4 translation [<xref rid="febs70033-bib-0047" ref-type="bibr">47</xref>]. Translation initiation site profiling experiments using the inhibitor harringtonine, which stalls ribosomes at the initiation sites [<xref rid="febs70033-bib-0049" ref-type="bibr">49</xref>], should be performed to investigate whether FTO translational regulation is more about start&#x02010;site selection than general translation efficiency.</p><p>The translatome experiment only showed very limited changes upon FTO knockdown, with only two transcripts being translationally upregulated and three transcripts being translationally downregulated. Immunoblotting experiments showed that COL1A1 and SMAD6 protein levels were accordingly downregulated, yet that DICER protein levels were not changed, although DICER was the most strongly regulated mRNA. It is possible that FTO knockdown did not reach levels low enough to broadly affect translation, and FTO knockout would have been a better strategy to reveal such regulation. Nonetheless, in a (patho)physiological setting, one would rather expect levels of FTO to vary than to be lost completely. For example, in humans, a recessive loss&#x02010;of&#x02010;function mutation in <italic toggle="yes">FTO</italic> leads to postnatal growth retardation, microcephaly, facial dimorphism, functional brain deficits and death within 30&#x02009;months of age [<xref rid="febs70033-bib-0050" ref-type="bibr">50</xref>].</p><p>FTO initially became known as the most significant genetic factor associated with human obesity. Its key role in fat metabolism was experimentally revealed by whole&#x02010;body knockout of <italic toggle="yes">Fto</italic> in mice, which resulted in decreased body weight in both males and females on normal chow and a significantly reduced weight gain on a high&#x02010;fat diet. Conversely, ubiquitous overexpression of FTO in mice led to increased body weight and fat mass in both males and females, observed across normal as well as high&#x02010;fat diet conditions (reviewed in [<xref rid="febs70033-bib-0020" ref-type="bibr">20</xref>]). Intriguingly, mutation of the uORF in the CEBPB gene in mice causing deficiency in C/EBP&#x003b2;&#x02010;LIP expression results in a metabolic phenotypes resembling those found in FTO knockout mice [<xref rid="febs70033-bib-0051" ref-type="bibr">51</xref>]. Although not investigated, this suggests that part of the FTO&#x02010;related phenotype in mice is caused through C/EBP&#x003b2; regulation.</p><p>Taking into account the many studies on the diverse and partially contradictory roles of FTO in cancer (reviewed in [<xref rid="febs70033-bib-0020" ref-type="bibr">20</xref>, <xref rid="febs70033-bib-0052" ref-type="bibr">52</xref>]), one must conclude that the effects of FTO on specific and global regulation of RNA demethylation can only be understood and eventually employed for therapeutic strategies in specific situations, e.g., a specific cancer type at a specific stage.</p></sec><sec sec-type="materials-and-methods" id="febs70033-sec-0010"><title>Materials and methods</title><sec id="febs70033-sec-0011"><title>Cell culture</title><p>MDA&#x02010;MB&#x02010;231 (RRID:CVCL_0062; cell line authentication by Eurofins Genomics, Ebersberg, Germany), HEK293T (RRID:CVCL_0063) and MEF [<xref rid="febs70033-bib-0051" ref-type="bibr">51</xref>] cells were cultured in DMEM, high glucose with GlutaMAX and pyruvate (Gibco, Thermo Fisher Scientific, Sittard, The Netherlands) supplemented with 10% FCS, 10&#x02009;m<sc>m</sc> HEPES and penicillin/streptomycin. MCF&#x02010;7 (RRID:CVCL_0031) cells were cultured in RPMI 1640 with GlutaMax and 25&#x02009;m<sc>m</sc> HEPES (Gibco, Thermo Fisher Scientific, Sittard, The Netherlands) supplemented with 10% FCS, 1&#x02009;m<sc>m</sc> pyruvate and penicillin/streptomycin. MCF10A (RRID:CVCL_0598) cells were cultured in DMEM/F12 containing 5% horse serum, 10&#x02009;m<sc>m</sc> HEPES, and 100&#x02009;U&#x000b7;mL<sup>&#x02212;1</sup> Penicillin/Streptomycin, supplemented with 20&#x02009;ng&#x000b7;mL<sup>&#x02212;1</sup> EGF, 100&#x02009;ng&#x000b7;mL<sup>&#x02212;1</sup> Cholera toxin, 10&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> insulin, and 0.5&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> hydrocortisone. All cell lines were incubated at 37&#x02009;&#x000b0;C with 5% CO<sub>2</sub> in a humidified incubator. All experiments were performed using Mycoplasma&#x02010;free cells, regularly verified by PCR.</p></sec><sec id="febs70033-sec-0012"><title>
<styled-content style="fixed-case" toggle="no">DNA</styled-content> constructs</title><p>Short hairpin RNA sequences targeting FTO or nontarget &#x02018;scrambled&#x02019; shRNA control (Sigma&#x02010;Aldrich, Merck, Dordrecht, The Netherlands) were ordered as forward and reverse oligos, they were annealed and inserted into the pLKO1puro vector using AgeI and EcoRI restriction sites. ShFTO1 fw: 5&#x02032;&#x02010;CCG GTC ACC AAG GAG ACT GCT ATT TCT CGA GAA ATA GCA GTC TCC TTG GTG ATT TTT G&#x02010;3&#x02032;, shFTO1 rv: 5&#x02032;&#x02010;AAT TCA AAA ATC ACC AAG GAG ACT GCT ATT TCT CGA GAA ATA GCA GTC TCC TTG GTG A&#x02010;3&#x02032;, shFTO2 fw: 5&#x02032;&#x02010;CCG GTA GTC TGA CTT GGT GTT AAA TCT CGA GAT TTA ACA CCA AGT CAG ACT ATT TTT G&#x02010;3&#x02032;, shFTO2 rv: 5&#x02032;&#x02010;AAT TCA AAA ATA GTC TGA CTT GGT GTT AAA TCT CGA GAT TTA ACA CCA AGT CAG ACT A&#x02010;3&#x02032;, shWTAP fw: 5&#x02032;&#x02010;CCG GAT GGC AAG AGA TGA GTT AAT TCT CGA GAA TTA ACT CAT CTC TTG CCA TTT TTT G&#x02010;3&#x02032;, shWTAP rv: 5&#x02032;&#x02010;AAT TCA AAA AAT GGC AAG AGA TGA GTT AAT TCT CGA GAA TTA ACT CAT CTC TTG CCA T&#x02010;3&#x02032;. For rescue of FTO expression, human FTO (from pCMV&#x02010;FTO, HG12125&#x02010;UT, Sino Biological, Eschborn, Germany) was subcloned and inserted into the pcDNA3.1+ expression vector using KnpI/XbaI. The 3xFLAG&#x02010;FTO construct was produced by annealing the following forward and reverse oligos to generate 3xFLAG&#x02010;N (fw: 5&#x02032;&#x02010;CTA GCT ATG GAC TAC AAA GAC CAT GAC GGT GAT TAT AAA&#x02010;3&#x02032;; rv: 5&#x02032;&#x02010;TAC TAG AAA TAT TAG TGG CAG TAC CAG AAA CAT CAG GTA TC&#x02010;3&#x02032;) and 3xFLAG&#x02010;C (fw: 5&#x02032;&#x02010;GAT CAT GAC ATC GAT TAC AAG GAT GAC GAT GAC AAG GGA A&#x02010;3&#x02032;; rv: 5&#x02032;&#x02010;TCG AAA GGG AAC AGT AGC AGT AGG AAC ATT AGC TAC AG&#x02010;3&#x02032;) sequences and ligating these together into the human FTO pcDNA3.1+ expression vector described above via NheI/HindIII restriction sites to produce a fusion at the N&#x02010;terminus of FTO. For the 3xFLAG control vector the 3xFLAG&#x02010;N and 3xFLAG&#x02010;C sequences were ligated into an empty pcDNA3.1+ expression vector using the same restriction sites. Subsequently, the 3xFLAG&#x02010;FTO and the 3xFLAG control sequences were cloned into the lentiviral expression vector pLVX&#x02010;IRES&#x02010;neo using NheI and XbaI restriction sites. For ectopic LIP expression, human LIP was cloned and inserted into the lentiviral expression vector pLVX&#x02010;IRES&#x02010;neo as described in [<xref rid="febs70033-bib-0040" ref-type="bibr">40</xref>].</p></sec><sec id="febs70033-sec-0013"><title>Knockdown cells</title><p>For knockdown cells, 3.8&#x02009;&#x000d7;&#x02009;10<sup>6</sup> HEK293T&#x000a0;cells were seeded in 10&#x02009;cm dishes one day prior to calcium phosphate transfection of pLKO.1 constructs along with pMDL&#x02010;RRE, pCMV&#x02010;VSVg and pRSV&#x02010;Rev expression constructs. After 2&#x02009;days virus was harvested and used for transduction of target cells followed by selection with either 0.25&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> (MDA&#x02010;MB&#x02010;231), 0.5&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> (MCF&#x02010;7) or 1&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> (MCF10A) puromycin. For ectopic LIP expression concomitant with nontarget &#x02018;scrambled&#x02019; sh control RNA or FTO sh RNAs in MDA&#x02010;MB&#x02010;231 cells, HEK293T&#x000a0;cells were cotransfected with pLKO.1 constructs and either human LIP pLVX&#x02010;IRESneo vector or empty pLVX&#x02010;IRESneo vector as a control along with pMDL&#x02010;RRE, pCMV&#x02010;VSVg and pRSV&#x02010;Rev expression constructs. Virus was harvested and used for transduction of target cells as described above and cells were selected with both puromycin (0.5&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup>) and Geneticin (1&#x02009;mg&#x000b7;mL<sup>&#x02212;1</sup>). For FTO&#x02010;overexpressing/rescued cells, MDA&#x02010;MB&#x02010;231 cells were seeded in 6&#x02010;well plates one day prior to FuGene transfection with pcDNA3.1+ empty vector or FTO according to the manufacturer's instructions. Cells were selected with 700&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> Geneticin.</p></sec><sec id="febs70033-sec-0014"><title>
<styled-content style="fixed-case" toggle="no">MDA</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">MB</styled-content>&#x02010;231 <styled-content style="fixed-case" toggle="no">FTO</styled-content> knockout cells and re&#x02010;expression of <styled-content style="fixed-case" toggle="no">3xFLAG</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">FTO</styled-content>
</title><p>Guide RNA 5&#x02032;&#x02010;CACCGCGGTGGGTGGAACTAAACCG&#x02010;3&#x02032; targeting FTO's fifth exon was designed using chopchop (<ext-link xlink:href="https://chopchop.cbu.uib.no/" ext-link-type="uri">https://chopchop.cbu.uib.no/</ext-link>). MDA&#x02010;MB&#x02010;231 cells were seeded in 6&#x02010;well plates 1&#x02009;day prior to transfection with pSpCas9(BB)&#x02010;2A&#x02010;Puro (PX459) V2.0 (a gift from Feng Zhang, Addgene plasmid #62988) using X&#x02010;treme GENE&#x02122; 360 DNA transfection reagent (Sigma&#x02010;Aldrich, Merck, Dordrecht, The Netherlands). After two days, cells were selected with 0.75&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> puromycin and individual clones were grown out and assayed for FTO expression by immunoblotting and for gene disruption by Sanger sequencing. To express 3xFLAG&#x02010;FTO or 3xFLAG in these cells, one FTO knockout clone was selected and lentivirally infected with supernatant from HEK293T&#x000a0;cells transfected with the 3xFLAG&#x02010;FTO or the 3xFLAG control pLVX&#x02010;IRES&#x02010;neo or empty vector plasmids respectively. Infected cells were selected using 1&#x02009;mg&#x000b7;mL<sup>&#x02212;1</sup> Geneticin.</p></sec><sec id="febs70033-sec-0015"><title>Immunoblotting</title><p>Cells were washed twice in ice&#x02010;cold PBS prior to harvesting by scraping in ice&#x02010;cold PBS. Cells were lysed by sonication in 50&#x02009;m<sc>m</sc> Tris pH 7.5, 150&#x02009;m<sc>m</sc> NaCl, 1&#x02009;m<sc>m</sc> EDTA, and 1% Triton&#x02010;X 100 supplemented with protease and phosphatase inhibitors (Roche, Woerden, The Netherlands). Equal amounts of protein were separated by SDS/PAGE using Mini&#x02010;PROTEAN&#x000ae; TGX&#x02122; Precast Protein Gels (#4561094; Bio&#x02010;Rad, Veenendaal, The Netherlands) and transferred to 0.2&#x02009;&#x003bc;<sc>m</sc> PVDF membranes by a Trans&#x02010;Blot Turbo System (Bio&#x02010;Rad, Veenendaal, The Netherlands), using RTA Midi kit (#1704273; Bio&#x02010;Rad, Veenendaal, The Netherlands) following the manufacturer's instructions. Blots were washed in TBS&#x02010;T (50&#x02009;m<sc>m</sc> Tris, 150&#x02009;m<sc>m</sc> NaCl, 0.02% Tween&#x02010;20) and blocked/stained in 5% milk or BSA in TBS&#x02010;T. Following overnight incubation with primary antibody, blots were stained with secondary antibodies (mouse or rabbit IgG HRP&#x02010;linked antibody, Thermo Fisher Scientific, Sittard, The Netherlands, 1:5000), and signals were visualized by chemiluminescence (ECL, Amersham, Merck, Dordrecht, The Netherlands) on an ImageQuant LAS 4000 mini biomolecular imager (GE Healthcare, Amersfoort, The Netherlands). The supplied software was used for image quantification. The following primary antibodies were used for detection: FTO: NB110&#x02010;60935, Novus Biologicals, Abingdon, UK (1:1666); &#x003b2;&#x02010;Actin: 691001, MP Bio, Heerlen, The Netherlands (1:5000); C/EBP&#x003b2;: ab32358, Abcam, Cambridge, UK (1:1000); WTAP: #56501 (1:1000), Cell Signaling Technology, Leiden, The Netherlands; COL1A1: #72026 (1:1000), Cell Signaling Technology, Leiden, The Netherlands; SMAD6: NB100&#x02010;56440, Novus Biologicals, Abingdon, UK (1:1000), FLAG&#x02010;M2: F&#x02010;3165, Sigma Aldrich, Merck, Dordrecht, The Netherlands&#x000a0;(1:1000). DICER protein levels were examined by tris&#x02010;acetate immunoblotting as described [<xref rid="febs70033-bib-0053" ref-type="bibr">53</xref>] with minor modifications. Briefly, 80&#x02009;&#x003bc;g protein per sample was loaded on 7% Tris&#x02010;acetate polyacrylamide gels (3% stacking) and transferred overnight at 20&#x02009;V to 0.45&#x02009;&#x003bc;m PVDF membrane by tank blotting in bicine/bis&#x02010;tris transfer buffer. The membranes were further processed as described, and the primary antibody was DICER (sc&#x02010;136&#x02009;979; Santa Cruz Biotechnology, Heidelberg, Germany&#x000a0;(1:1000)).</p></sec><sec id="febs70033-sec-0016"><title>
<styled-content style="fixed-case" toggle="no">RT</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">qPCR</styled-content>
</title><p>RNA was isolated from cells using the RNeasy Kit (Qiagen, Venlo, The Netherlands) according to the manufacturer's instructions. 1&#x02009;&#x003bc;g of total RNA was reverse transcribed using a Transcriptor First Strand cDNA Synthesis Kit (Roche, Woerden, The Netherlands) with random hexamer primers. Gene expression was analyzed using SYBR Green Master Mix (Bio&#x02010;Rad, Veenendaal, The Netherlands) on a LightCycler 480 (Roche, Woerden, The Netherlands) and normalized to &#x003b2;&#x02010;actin expression. Oligo sequences are listed in Table&#x000a0;<xref rid="febs70033-tbl-0001" ref-type="table">1</xref>.</p><table-wrap position="float" id="febs70033-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Sequences of oligonucleotides used in this study.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Gene</th><th align="left" valign="bottom" rowspan="1" colspan="1">Forward primer 5&#x02032;&#x02010;3&#x02032;</th><th align="left" valign="bottom" rowspan="1" colspan="1">Reversed primer 5&#x02032;&#x02010;3&#x02032;</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ACTB</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CCAACCGCGAGAAGATGA</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CCAGAGGCGTACAGGGATAG</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ALKBH5</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CGGCGAAGGCTACACTTACG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CCACCAGCTTTTGGATCACCA</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">COL12A1</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>ATCCCATACAACGGGCAAGG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>AATAAGCACGTGCGCAAACA</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CTHRC1</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>ATCCCCAAGGGGAAGCAAAAG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>GCTGGCCCTTGTAAGCACA</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">E2F1</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CCTGGAAACTGACCATCAGTACCT</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>GGATTTCACACCTTTTCCTGGAT</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">FN1</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CGGTGGCTGTCAGTCAAAG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>AAACCTCGGCTTCCTCCATAA</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">FTO</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>GGAGGGTGTGACAAATGCTGTG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>GCAGAGGCATCGAAGCATCATC</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">LRRC15</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CTGCTGGCTATGCCACTGAA</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>GAGCAGGTACACTCGCTAGG</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">MMP1</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CATGCTTTTCAACCAGGCCC</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>GTCCAAGAGAATGGCCGAGT</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SMARCD3</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>ACTGGATCAAACCATCATGCG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CAATGCTGCCGTCGGAATC</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">TNC</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>TCCCAGTGTTCGGTGGATCT</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>TTGATGCGATGTGTGAAGACA</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">SMARCD3</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>ACTGGATCAAACCATCATGCG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CAATGCTGCCGTCGGAATC</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">MYC</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>GGACCCGCTTCTCTGAAAGG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>TAACGTTGAGGGGCATCGTC</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">HPRT</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CATTATGCTGAGGATTTGGAAAGG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CTTGAGCACACAGAGGGCTACA</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">DICER1</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>TTCAGATCTCAAGGTTGGGGA</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>TCAAGGCGACATAGCAAGTCAT</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CEBPb</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>TTTCGAAGTTGATGCAATCG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CAACAAGCCCGTAGGAACAT</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EEF1A1</italic>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CGGTCTCAGAACTGTTTGTTTC</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>AAACCAAAGTGGTCCACAAA</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FTO geno</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CATGTCCTGAGCAGAGGTTGT</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>CTGGTCATCTCCTGCCCTTG</monospace>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FTO geno seq</td><td align="left" valign="top" rowspan="1" colspan="1">
<monospace>GTCACCTACTTATAAGGGATTGATTAAAG</monospace>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec id="febs70033-sec-0017"><title>Cell migration assays</title><p>Cells were serum starved in their canonical medium with 0.1&#x02013;1% serum. For scratch assays, 15&#x02009;000 MDA&#x02010;MB&#x02010;231 cells were seeded in 96&#x02010;well ImageLock plates compatible with the Incucyte Zoom system (Sartorius, Nieuwegein, The Netherlands). 24&#x02009;h after seeding a scratch wound was made using the WoundMaker Tool (Sartorius, Nieuwegein, The Netherlands) and the cells were incubated in low&#x02010;serum medium after washing twice. Cells were imaged every 2&#x02009;h for 48&#x02009;h and the relative wound density was calculated using the provided software according to the manufacturer's instructions. For Transwell migration assays, 20&#x02009;000 cells were seeded in 0.1&#x02013;1% FCS for MDA&#x02010;MB&#x02010;231 cells and in 1% horse serum supplemented with EGF, Cholera toxin, insulin, and hydrocortisone for MCF10A cells in the upper compartment of 8&#x02009;&#x003bc;m Corning Transwell polycarbonate membrane cell culture inserts (3422; Corning, Amsterdam, The Netherlands) and attracted to the bottom by medium with 10% serum (MDA&#x02010;MB&#x02010;231 cells) or with 5% horse serum supplemented with EGF, Cholera toxin, insulin, and hydrocortisone (MCF10A cells). After 48&#x02009;h, the cells were fixed with 96% ethanol on ice and stained with 0.5% crystal violet in 10% ethanol in water. Inserts were rinsed with demi water, air dried and imaged using a Leica DMC2900 digital microscope. For quantification, at least 3 inserts with 3 random images from each insert per condition were analyzed using ImageJ. To determine the effect of entacapone on cell migration, cells were pretreated with 25&#x02009;&#x003bc;<sc>m</sc> entacapone (SML&#x02010;0654; Sigma&#x02010;Aldrich, Dordrecht, The Netherlands) for 24&#x02009;h prior to seeding as described with 25&#x02009;&#x003bc;<sc>m</sc> entacapone in both low&#x02010;serum and attractant media.</p></sec><sec id="febs70033-sec-0018"><title>Clonogenic and cell viability assays</title><p>For clonogenic assays, 3000 cells were seeded in 5&#x02009;mL of their normal medium in 6&#x02010;well plates and incubated for 7&#x02009;days. Cells were washed twice in PBS, fixed in 96% ethanol on ice and washed again twice in PBS before staining with 0.5% crystal violet in 10% ethanol in water. Wells were washed with demi water, air dried and imaged prior to quantification using <sc>imagej</sc>. For cell viability assays, 2500 (MDA&#x02010;MB&#x02010;231) or 7500 (MCF&#x02010;7) cells were seeded per well in 96&#x02010;well plates with the indicated drug concentrations of entacapone and/or HLM006474 (SML1260; Sigma&#x02010;Aldrich, Merck, Dordrecht, The Netherlands). After 72&#x02009;h cell viability was determined using a CellTiter&#x02010;Fluor&#x02122; Cell Viability Assay (Promega, Leiden, The Netherlands) according to the manufacturer's instructions. For MCF10A, FTO knockdown and &#x02018;scrambled&#x02019; control cells, 3000 cells were seeded per well in 96 well plates in the presence of puromycin and the culture medium was renewed after 48&#x02009;h. The relative number of viable cells as a measure of cell proliferation was&#x000a0;determined after 72&#x02009;h using a CellTiter&#x02010;Glo&#x02122; Assay (Promega, Leiden, The Netherlands) according to the manufacturer's instructions.</p></sec><sec id="febs70033-sec-0019"><title>
<styled-content style="fixed-case" toggle="no">m6A</styled-content> dot blotting</title><p>mRNA was isolated from total RNA using Dynabeads&#x02122; Oligo(dT)25 (Thermo Fisher Scientific, Sittard, The Netherlands) and diluted to 50 (MDA&#x02010;MB&#x02010;213) or 75 (MCF&#x02010;7) ng&#x000b7;&#x003bc;L<sup>&#x02212;1</sup> in RNase free water. Samples were denatured for 3&#x02009;min at 95 degrees and 2&#x02009;&#x003bc;L was spotted on Hybond&#x000ae;&#x02010;N+ hybridization membrane (Amersham, Merck, Dordrecht, The Netherlands). mRNA was crosslinked to the membrane using a Stratalinker 2400 UV crosslinker (twice 120&#x02009;000&#x02009;&#x003bc;J&#x000b7;cm<sup>&#x02212;2</sup>) and the membrane was washed for 10&#x02009;min in TBS&#x02010;T. Membranes were stained with 0.05% methylene blue in 0.5&#x02009;<sc>m</sc> acetic acid for 15&#x02009;min and washed three times for 2&#x02009;min in Milli&#x02010;Q water. Following imaging for loading control the membrane was blocked in 5% BSA in TBS&#x02010;T and incubated overnight at 4&#x02009;&#x000b0;C using N6&#x02010;methyladenosine antibody (ab151230; Abcam). The next day, the membranes were washed three times in TBS&#x02010;T, stained with 1:5000 rabbit IgG HRP&#x02010;linked antibody (Thermo Fisher Scientific, Sittard, The Netherlands) for 1&#x02009;h and washed again three times in TBS&#x02010;T. The m6A signal was developed using chemiluminescence as described for immunoblotting.</p></sec><sec id="febs70033-sec-0020"><title>Ribosome profiling</title><p>Preparation of ribosome&#x02010;protected footprints for deep sequencing was essentially performed as described [<xref rid="febs70033-bib-0054" ref-type="bibr">54</xref>]. Briefly, 30&#x02009;&#x000d7;&#x02009;10<sup>6</sup> cells were harvested in ice&#x02010;cold PBS with 100&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> cycloheximide (Sigma&#x02010;Aldrich, Merck, Dordrecht, The Netherlands) and 10% was kept aside for RNA&#x02010;sequencing. Cells were lysed in lysis buffer (20&#x02009;m<sc>m</sc> Tris/HCl pH 7.5, 10&#x02009;m<sc>m</sc> MgCl<sub>2</sub>, 100&#x02009;m<sc>m</sc> KCl, 1% Triton X&#x02010;100, 2&#x02009;m<sc>m</sc> DTT, 100&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> cycloheximide and protease inhibitors (EDTA&#x02010;free, Roche, Woerden, The Netherlands)) and lysates were treated with RNAseI (Ambion, Thermo Fisher Scientific, Sittard, The Netherlands) before ultracentrifugation over a sucrose gradient using an SW&#x02010;41Ti rotor at 222,200 x g&#x02009;for 2&#x02009;h at 4 &#x000b0;C. Cytosolic ribosome fractions were collected and digested with PCR grade proteinase K (Roche, Woerden, The Netherlands) in the presence of 1% SDS prior to RNA isolation using TRIzol (Invitrogen, Thermo Fisher Scientific, Sittard, The Netherlands). RNA fragments were run on a denaturing urea polyacrylamide gel and correctly sized fragments were eluted in 0.3&#x02009;M sodium acetate pH 5.5 and recovered by ethanol precipitation. RNA was 3&#x02032; dephosphorylated using T4 Polynucleotide Kinase (NEB, Biok&#x000e9;, Leiden, The Netherlands) and preadenylated linkers were ligated to the RNA fragments using T4 RNA Ligase 2 K277Q (NEB, Biok&#x000e9;, Leiden, The Netherlands). After 5&#x02032; deadenlyase and RecJ exonuclase treatment, fragments were cleaned using an Oligo Clean &#x00026; Concentrator kit (Zymo, Freiburg Germany) before rRNA depletion by subtractive hybridization using MyOne Streptavidin C1 DynaBeads (Thermo Fischer Scientific, Sittard, The Netherlands) and biotinylated rRNA oligos. Following ethanol precipitation, samples were reverse transcribed using SuperScript III RT (Invitrogen, Thermo Fisher Scientific, Sittard, The Netherlands) and again ethanol precipitated prior to gel purification using urea PAGE. Fragments were circularized by CircLigase II (Epicentre, LGC, Den Haag, The Netherlands), recovered by ethanol precipitation, and subjected to library construction PCR using Q5 HF mastermix (NEB, Biok&#x000e9;, Leiden, The Netherlands), which was size selected using nondenaturing PAGE and recovered by ethanol precipitation. Library quality was confirmed using a Bioanalyzer 2100 (Agilent, Middelburg, The Netherlands) with the DNA 7500 kit (Agilent, Middelburg, The Ntherlands) and libraries were quantified by Qubitt dsDNA BR assay (Thermo Fisher Scientific, Sittard, The Netherlands) prior to high&#x02010;throughput 75&#x02009;bp single&#x02010;end sequencing on an Illumina NextSeq machine. Translation efficiencies were calculated from ribosome profiling and RNA sequencing data using RiboDiff version 0.2.1 [<xref rid="febs70033-bib-0055" ref-type="bibr">55</xref>] and differential codon occupancy was determined using diricore as described [<xref rid="febs70033-bib-0039" ref-type="bibr">39</xref>].</p></sec><sec id="febs70033-sec-0021"><title>
<styled-content style="fixed-case" toggle="no">RNA</styled-content> sequencing</title><p>RNA was isolated from a portion of cells processed for ribosome profiling using the RNeasy kit (Qiagen, Venlo, The Netherlands). mRNA was isolated by NEXTFLEX&#x000ae; Poly(A) Beads (Perkin Elmer, Revvity, Groningen, The Netherlands), quality checked by RNA 6000 nano chip (Agilent, Middelburg, The Netherlands) on a Bioanalyzer 2100 (Agilent, Middelburg, The Netherlands) and sequencing libraries were prepared using NEXTFLEX&#x000ae; Rapid Directional qRNA&#x02010;Seq&#x02122; Library Prep Kit (Perkin Elmer, Revvity, Groningen, The Netherlands) according to the manufacturer's instructions. Library quality was confirmed using a Bioanalyzer 2100 (Agilent, Middelburg, The Netherlands) with the DNA 7500 kit (Agilent, Middelburg, The Netherlands) and libraries were quantified by Qubitt dsDNA BR assay (Thermo Fisher Scientific, Sittard, The Netherlands) prior to high&#x02010;throughput 75&#x02009;bp paired&#x02010;end sequencing on an Illumina NextSeq 500 machine. Reads were demultiplexed by sample&#x02010;specific barcodes and changed to fastq files using bcl2fastq version 1.8.4 (Illumina, Eindhoven, The Netherlands). An in&#x02010;house Perl script was used to remove barcodes, and low&#x02010;quality trimming was performed on both mates using Cutadapt [<xref rid="febs70033-bib-0056" ref-type="bibr">56</xref>] version 1.12 (settings: q&#x02009;=&#x02009;15, O&#x02009;=&#x02009;5, e&#x02009;=&#x02009;0.1, m&#x02009;=&#x02009;20) prior to poly A tail removal using poly A or poly T as an adapter. Reads shorter than 20 bases after trimming were discarded. The trimmed reads were aligned to GRCh38, Ensembl release 95 using HISAT2 [<xref rid="febs70033-bib-0057" ref-type="bibr">57</xref>] version 2.1.0 (settings: k&#x02009;=&#x02009;1000, &#x02010;&#x02010;norc). Reads were only mapped against the forward strand. An in&#x02010;house Perl script was used to remove reads that mapped to multiple genes. A script from Bio Scientific (dqRNASeq; settings: s&#x02009;=&#x02009;8, q&#x02009;=&#x02009;0, m&#x02009;=&#x02009;1) was used to determine the number of unique fragments per transcript. Unique fragments per gene were determined using an in&#x02010;house Perl script. Differentially expressed genes were identified using the Bioconductor (<ext-link xlink:href="https://www.bioconductor.org/" ext-link-type="uri">https://www.bioconductor.org/</ext-link>) package edgeR&#x000a0; [<xref rid="febs70033-bib-0058" ref-type="bibr">58</xref>] version 3.32.1 using R version 4.0.3. Gene expression was normalized using trimmed mean of m&#x02010;values (TMM), and multiple testing was corrected for using Benjamini&#x02010;Hochberg correction. Genes with a false discovery rate (FDR) &#x0003c;0.05 and a fold change of at least 1.5&#x02010;fold were considered differentially expressed. Data were analyzed further using custom R&#x02010;scripts and topGO version 2.44.0. For gene set enrichment analysis (GSEA), the desktop application (<ext-link xlink:href="https://www.gsea-msigdb.org/gsea" ext-link-type="uri">https://www.gsea&#x02010;msigdb.org/gsea</ext-link>, The Broad Institute) was used to compare the ranked gene list to hallmark signatures using the gene set permutation type with 1000 permutations [<xref rid="febs70033-bib-0036" ref-type="bibr">36</xref>].</p></sec><sec id="febs70033-sec-0022"><title>
<styled-content style="fixed-case" toggle="no">mRNA</styled-content> stability assays</title><p>Cells were seeded in 6&#x02009;cm dishes one day prior to treatment with 1&#x02009;&#x003bc;g&#x000b7;mL<sup>&#x02212;1</sup> actinomycin D (Sigma&#x02010;Aldrich, Merck, Dordrecht, The Netherlands) for the indicated time. Cells were washed twice in ice&#x02010;cold PBS and harvested by scraping in ice&#x02010;cold PBS. RNA was isolated and processed to cDNA as described above for RT&#x02010;qPCR. The fraction of remaining mRNA after actinomycin D treatment was calculated by the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method.</p></sec><sec id="febs70033-sec-0023"><title>
<styled-content style="fixed-case" toggle="no">MeRIP</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">qPCR</styled-content> analysis</title><p>mRNA was isolated as described above and 1&#x02009;&#x003bc;g was precipitated with 2&#x02009;&#x003bc;L anti&#x02010;m6A antibody (ab151230; Abcam, Cambridge, UK) or normal rabbit IgG (sc&#x02010;2027; Santa Cruz Biotechnology, Heidelberg, Germany) in IPP buffer (10&#x02009;m<sc>m</sc> Tris/HCl (pH 7.5), 150&#x02009;m<sc>m</sc> NaCl, 0.1% NP&#x02010;40, 1&#x02009;m<sc>m</sc> DTT) at 4&#x02009;&#x000b0;C for 4&#x02009;h under constant rotation. Then, 20&#x02009;&#x003bc;L prewashed Dynabeads Protein A (Thermo Fischer Scientific, Sittard, The Netherlands) in IPP buffer was added, followed by another 2&#x02009;h on the rotator at 4&#x02009;&#x000b0;C. The beads were washed 5x in IPP buffer and transferred to fresh tubes after the 3rd and 5th washes. Samples were eluted twice in RLT+ buffer (Qiagen, Venlo, The Netherlands) with &#x003b2;&#x02010;mercaptoethanol for 10&#x02009;min at room temperature and RNA was recovered by ethanol precipitation. Pellets were resuspended in nuclease&#x02010;free water and subjected to reverse transcription along with 100&#x02009;ng mRNA input samples followed by RT&#x02010;qPCR analysis. Transcript recovery over input was calculated and normalized to a positive control mRNA (EEF1A1).</p></sec><sec id="febs70033-sec-0024"><title>
<styled-content style="fixed-case" toggle="no">RNA</styled-content> immunoprecipitation (<styled-content style="fixed-case" toggle="no">RIP</styled-content>)</title><p>FTO&#x02010;specific RIP was performed as described in [<xref rid="febs70033-bib-0054" ref-type="bibr">54</xref>]. MDA&#x02010;MB&#x02010;231 FTO knockout cells expressing 3xFLAG&#x02010;FTO and controls (empty vector or 3xFLAG) were seeded in 10&#x02009;cm plates. After 24&#x02009;h, cells were washed, harvested in ice&#x02010;cold PBS, lysed, and pooled from two plates per condition. Lysates were sonicated and treated with DNase after which input controls for protein and RNA were taken (5% each).</p><p>Then lysates were pre&#x02010;cleared with Protein A&#x02010;coupled magnetic beads and incubated with anti&#x02010;FLAG antibody&#x02010;conjugated beads or Protein A&#x02010;coupled beads for the &#x0201c;no antibody&#x0201d; control, both pre&#x02010;treated with yeast tRNA for blocking. After 4&#x02009;h of incubation, the beads were washed four times and 10% of the beads were separated to check success of the immunoprecipitation. Co&#x02010;precipitated RNA was eluted from the rest of the beads using RLT buffer (RNeasy Mini Kit, Qiagen, Venlo, The Netherlands) supplemented with &#x003b2;&#x02010;mercaptoethanol. RNA was precipitated overnight at &#x02212;80&#x02009;&#x000b0;C, treated with DNase, and reverse transcribed into cDNA as described above which was used for qPCR to detect CEBPB mRNA levels. CEBPB mRNA enrichment was calculated using the &#x00394;&#x00394;CT method as described in [<xref rid="febs70033-bib-0055" ref-type="bibr">55</xref>].</p></sec><sec id="febs70033-sec-0025"><title>Statistical analyses</title><p>Analysis of ribosome and RNA&#x02010;sequencing data is described above. For all remaining analyses Student's <italic toggle="yes">t</italic>&#x02010;test or one&#x02010;, or two&#x02010;way ANOVA with Dunnett's <italic toggle="yes">post hoc</italic> test (when appropriate) was used as described in the figure legends. Statistical testing was performed using GraphPad Prism 6 and statistically significant differences are indicated: *<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.0001.</p></sec></sec><sec sec-type="COI-statement" id="febs70033-sec-0027"><title>Conflict of interest</title><p>The authors declare no competing interests.</p></sec><sec id="febs70033-sec-0028"><title>Author contributions</title><p>HRZ and CFC conceived the project with input from CM. HRZ, CM and GK performed experiments and analyzed the data. FL&#x02010;P provided expertise and lab resources on the ribosome profiling experiments. RW helped with mapping and processing the RNA&#x02010;sequencing data. ES mapped and analyzed the ribosome profiling data. HRZ, CM and CFC wrote the manuscript. CFC and FL&#x02010;P supervised the work.</p></sec><sec id="febs70033-sec-0029"><sec disp-level="2" id="febs70033-sec-0031"><title>Peer review</title><p>The peer review history for this article is available at <ext-link xlink:href="https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/febs.70033" ext-link-type="uri">https://www.webofscience.com/api/gateway/wos/peer&#x02010;review/10.1111/febs.70033</ext-link>.</p></sec></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="febs70033-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Table S1.</bold> Data transcriptome analysis of MDA&#x02010;MB&#x02010;231 cells.</p><p>
<bold>Table S2.</bold> Data ribosome profiling of MDA&#x02010;MB&#x02010;231 cells.</p></caption><media xlink:href="FEBS-292-2688-s001.pdf"/></supplementary-material></sec></body><back><ack id="febs70033-sec-0026"><title>Acknowledgements</title><p>The authors would like to thank Britt Sterken, Christy Hong and Thamar Jessurun Lobo for experimental advice. This work was supported by a travel grant from the Boehringer Ingelheim Fonds awarded to HRZ, and a KWF (#10080) grant awarded to CFC. FL&#x02010;P is supported by grants from the European Research Council &#x02018;DualRP&#x02019; (ERC StG No. 759579) and the German Research Foundation (DFG 504774163 and DFG 545215964). We thank the ERIBA&#x02010;UMCG sequencing facility for help in preparing the RNA&#x02010;seq libraries.</p></ack><sec sec-type="data-availability" id="febs70033-sec-0030"><title>Data availability statement</title><p>RNA&#x02010;seq and the Ribo&#x02010;seq data that support the findings in this study are openly available in the ArrayExpress database at EMBL&#x02010;EBI (<ext-link xlink:href="http://www.ebi.ac.uk/arrayexpress" ext-link-type="uri" specific-use="software is-supplemented-by">www.ebi.ac.uk/arrayexpress</ext-link>) under accession numbers E&#x02010;MTAB&#x02010;14808 and E&#x02010;MTAB&#x02010;14809.</p></sec><ref-list id="febs70033-bibl-0001" content-type="cited-references"><title>References</title><ref id="febs70033-bib-0001"><label>1</label><mixed-citation publication-type="book" id="febs70033-cit-0001">
<string-name>
<surname>Zhao</surname>, <given-names>B. S.</given-names>
</string-name>, <string-name>
<surname>Roundtree</surname>, <given-names>I. A.</given-names>
</string-name> &#x00026; <string-name>
<surname>He</surname>, <given-names>C.</given-names>
</string-name> (<year>2016</year>) <source>Post&#x02010;Transcriptional Gene Regulation by mRNA Modifications</source>, <publisher-name>Nature Publishing Group</publisher-name>, <fpage>31</fpage>&#x02013;<lpage>42</lpage>.</mixed-citation></ref><ref id="febs70033-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="febs70033-cit-0002">
<string-name>
<surname>Meyer</surname>
<given-names>KD</given-names>
</string-name> &#x00026; <string-name>
<surname>Jaffrey</surname>
<given-names>SR</given-names>
</string-name> (<year>2014</year>) <article-title>The dynamic epitranscriptome: N6&#x02010;methyladenosine and gene expression control</article-title>. <source>Nat Rev Mol Cell Biol</source>
<volume>15</volume>, <fpage>313</fpage>&#x02013;<lpage>326</lpage>.<pub-id pub-id-type="pmid">24713629</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="febs70033-cit-0003">
<string-name>
<surname>Wei</surname>
<given-names>CM</given-names>
</string-name> &#x00026; <string-name>
<surname>Moss</surname>
<given-names>B</given-names>
</string-name> (<year>1977</year>) <article-title>Nucleotide sequences at the N6&#x02010;methyladenosine sites of HeLa cell messenger ribonucleic acid</article-title>. <source>Biochemistry</source>
<volume>16</volume>, <fpage>1672</fpage>&#x02013;<lpage>1676</lpage>.<pub-id pub-id-type="pmid">856255</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="febs70033-cit-0004">
<string-name>
<surname>Harper</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Miceli</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>RJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Manley</surname>
<given-names>JL</given-names>
</string-name> (<year>1990</year>) <article-title>Sequence specificity of the human mRNA N6&#x02010;adenosine methylase in vitro</article-title>. <source>Nucleic Acids Res</source>
<volume>18</volume>, <fpage>5735</fpage>&#x02013;<lpage>5741</lpage>.<pub-id pub-id-type="pmid">2216767</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="febs70033-cit-0005">
<string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yue</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>X</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2014</year>) <article-title>A METTL3&#x02010;METTL14 complex mediates mammalian nuclear RNA N6&#x02010;adenosine methylation</article-title>. <source>Nat Chem Biol</source>
<volume>10</volume>, <fpage>93</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">24316715</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="febs70033-cit-0006">
<string-name>
<surname>Dominissini</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Moshitch&#x02010;Moshkovitz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Salmon&#x02010;Divon</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ungar</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Osenberg</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cesarkas</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jacob&#x02010;Hirsch</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Amariglio</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kupiec</surname>
<given-names>M</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2012</year>) <article-title>Topology of the human and mouse m6A RNA methylomes revealed by m6A&#x02010;seq</article-title>. <source>Nature</source>
<volume>485</volume>, <fpage>201</fpage>&#x02013;<lpage>206</lpage>.<pub-id pub-id-type="pmid">22575960</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="febs70033-cit-0007">
<string-name>
<surname>Geula</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Moshitch&#x02010;Moshkovitz</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dominissini</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mansour</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Kol</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Salmon&#x02010;Divon</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hershkovitz</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Peer</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mor</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Manor</surname>
<given-names>YS</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2015</year>) <article-title>m6A mRNA methylation facilitates resolution of naive pluripotency toward differentiation</article-title>. <source>Science</source>
<volume>347</volume>, <fpage>1002</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">25569111</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="febs70033-cit-0008">
<string-name>
<surname>Ke</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Pandya&#x02010;Jones</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fak</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Vagbo</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Geula</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hanna</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Black</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Darnell</surname>
<given-names>JE</given-names>
<suffix>Jr</suffix>
</string-name> &#x00026; <string-name>
<surname>Darnell</surname>
<given-names>RB</given-names>
</string-name> (<year>2017</year>) <article-title>M(6)a mRNA modifications are deposited in nascent pre&#x02010;mRNA and are not required for splicing but do specify cytoplasmic turnover</article-title>. <source>Genes Dev</source>
<volume>31</volume>, <fpage>990</fpage>&#x02013;<lpage>1006</lpage>.<pub-id pub-id-type="pmid">28637692</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="febs70033-cit-0009">
<string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Gomez</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hon</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Yue</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Parisien</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Dai</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Jia</surname>
<given-names>G</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2014</year>) <article-title>N6&#x02010;methyladenosine&#x02010;dependent regulation of messenger RNA stability</article-title>. <source>Nature</source>
<volume>505</volume>, <fpage>117</fpage>&#x02013;<lpage>120</lpage>.<pub-id pub-id-type="pmid">24284625</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="febs70033-cit-0010">
<string-name>
<surname>Zhou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Jaffrey</surname>
<given-names>SR</given-names>
</string-name> &#x00026; <string-name>
<surname>Qian</surname>
<given-names>SB</given-names>
</string-name> (<year>2015</year>) <article-title>Dynamic m(6)a mRNA methylation directs translational control of heat shock response</article-title>. <source>Nature</source>
<volume>526</volume>, <fpage>591</fpage>&#x02013;<lpage>594</lpage>.<pub-id pub-id-type="pmid">26458103</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="febs70033-cit-0011">
<string-name>
<surname>Mao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>XM</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shen</surname>
<given-names>B</given-names>
</string-name> &#x00026; <string-name>
<surname>Qian</surname>
<given-names>SB</given-names>
</string-name> (<year>2019</year>) <article-title>M(6)a in mRNA coding regions promotes translation via the RNA helicase&#x02010;containing YTHDC2</article-title>. <source>Nat Commun</source>
<volume>10</volume>, <fpage>5332</fpage>.<pub-id pub-id-type="pmid">31767846</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="febs70033-cit-0012">
<string-name>
<surname>Wu</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhuang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name> &#x00026; <string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name> (<year>2021</year>) <article-title>m6A methylation promotes white&#x02010;to&#x02010;beige fat transition by facilitating Hif1a translation</article-title>. <source>EMBO Rep</source>
<volume>22</volume>, <elocation-id>e52348</elocation-id>.<pub-id pub-id-type="pmid">34569703</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="febs70033-cit-0013">
<string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>BS</given-names>
</string-name>, <string-name>
<surname>Roundtree</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Weng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>H</given-names>
</string-name> &#x00026; <string-name>
<surname>He</surname>
<given-names>C</given-names>
</string-name> (<year>2015</year>) <article-title>N(6)&#x02010;methyladenosine modulates messenger RNA translation efficiency</article-title>. <source>Cell</source>
<volume>161</volume>, <fpage>1388</fpage>&#x02013;<lpage>1399</lpage>.<pub-id pub-id-type="pmid">26046440</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="febs70033-cit-0014">
<string-name>
<surname>Zaccara</surname>
<given-names>S</given-names>
</string-name> &#x00026; <string-name>
<surname>Jaffrey</surname>
<given-names>SR</given-names>
</string-name> (<year>2020</year>) <article-title>A unified model for the function of YTHDF proteins in regulating m(6)A&#x02010;modified mRNA</article-title>. <source>Cell</source>
<volume>181</volume>, <fpage>1582</fpage>&#x02013;<lpage>1595</lpage>.<pub-id pub-id-type="pmid">32492408</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="febs70033-cit-0015">
<string-name>
<surname>Jia</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Dai</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lindahl</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Pan</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>YG</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2011</year>) <article-title>N6&#x02010;methyladenosine in nuclear RNA is a major substrate of the obesity&#x02010;associated FTO</article-title>. <source>Nat Chem Biol</source>
<volume>7</volume>, <fpage>885</fpage>&#x02013;<lpage>887</lpage>.<pub-id pub-id-type="pmid">22002720</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="febs70033-cit-0016">
<string-name>
<surname>Zheng</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Dahl</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Niu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fedorcsak</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Vagbo</surname>
<given-names>CB</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>SH</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2013</year>) <article-title>ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility</article-title>. <source>Mol Cell</source>
<volume>49</volume>, <fpage>18</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">23177736</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="febs70033-cit-0017">
<string-name>
<surname>Tang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Klukovich</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Klungland</surname>
<given-names>A</given-names>
</string-name> &#x00026; <string-name>
<surname>Yan</surname>
<given-names>W</given-names>
</string-name> (<year>2018</year>) <article-title>ALKBH5&#x02010;dependent m6A demethylation controls splicing and stability of long 3&#x02032;&#x02010;UTR mRNAs in male germ cells</article-title>. <source>Proc Natl Acad Sci</source>
<volume>115</volume>, <fpage>E325</fpage>&#x02013;<lpage>E333</lpage>.<pub-id pub-id-type="pmid">29279410</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="febs70033-cit-0018">
<string-name>
<surname>Fischer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Emmerling</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Vierkotten</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Peters</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Bruning</surname>
<given-names>JC</given-names>
</string-name> &#x00026; <string-name>
<surname>Ruther</surname>
<given-names>U</given-names>
</string-name> (<year>2009</year>) <article-title>Inactivation of the Fto gene protects from obesity</article-title>. <source>Nature</source>
<volume>458</volume>, <fpage>894</fpage>&#x02013;<lpage>898</lpage>.<pub-id pub-id-type="pmid">19234441</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="febs70033-cit-0019">
<string-name>
<surname>Goodarzi</surname>
<given-names>MO</given-names>
</string-name> (<year>2018</year>) <article-title>Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications</article-title>. <source>Lancet Diabetes Endocrinol</source>
<volume>6</volume>, <fpage>223</fpage>&#x02013;<lpage>236</lpage>.<pub-id pub-id-type="pmid">28919064</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="febs70033-cit-0020">
<string-name>
<surname>Zuidhof</surname>
<given-names>HR</given-names>
</string-name> &#x00026; <string-name>
<surname>Calkhoven</surname>
<given-names>CF</given-names>
</string-name> (<year>2022</year>) <article-title>Oncogenic and tumor&#x02010;suppressive functions of the RNA demethylase FTO</article-title>. <source>Cancer Res</source>
<volume>82</volume>, <fpage>2201</fpage>&#x02013;<lpage>2212</lpage>.<pub-id pub-id-type="pmid">35303057</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="febs70033-cit-0021">
<string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Weng</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Weng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zuo</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nachtergaele</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2017</year>) <article-title>FTO plays an oncogenic role in acute myeloid leukemia as a N(6)&#x02010;Methyladenosine RNA demethylase</article-title>. <source>Cancer Cell</source>
<volume>31</volume>, <fpage>127</fpage>&#x02013;<lpage>141</lpage>.<pub-id pub-id-type="pmid">28017614</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="febs70033-cit-0022">
<string-name>
<surname>Qing</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Dong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Gao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Prince</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Tan</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Wetzel</surname>
<given-names>C</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2021</year>) <article-title>R&#x02010;2&#x02010;hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m(6)a/PFKP/LDHB axis</article-title>. <source>Mol Cell</source>
<volume>81</volume>, <fpage>922</fpage>&#x02013;<lpage>939</lpage>.<pub-id pub-id-type="pmid">33434505</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="febs70033-cit-0023">
<string-name>
<surname>Niu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Liang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Xiong</surname>
<given-names>XF</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>B</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2019</year>) <article-title>RNA N6&#x02010;methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3</article-title>. <source>Mol Cancer</source>
<volume>18</volume>, <fpage>46</fpage>.<pub-id pub-id-type="pmid">30922314</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="febs70033-cit-0024">
<string-name>
<surname>Cui</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Ye</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Qu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>CG</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2017</year>) <article-title>M(6)a RNA methylation regulates the self&#x02010;renewal and tumorigenesis of glioblastoma stem cells</article-title>. <source>Cell Rep</source>
<volume>18</volume>, <fpage>2622</fpage>&#x02013;<lpage>2634</lpage>.<pub-id pub-id-type="pmid">28297667</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="febs70033-cit-0025">
<string-name>
<surname>Lebert</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Lester</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Powell</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Seal</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>McCarthy</surname>
<given-names>J</given-names>
</string-name> (<year>2018</year>) <article-title>Advances in the systemic treatment of triple&#x02010;negative breast cancer</article-title>. <source>BMJ</source>
<volume>381</volume>, <elocation-id>e071674</elocation-id>.</mixed-citation></ref><ref id="febs70033-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="febs70033-cit-0026">
<string-name>
<surname>Fulford</surname>
<given-names>LG</given-names>
</string-name>, <string-name>
<surname>Reis&#x02010;Filho</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Ryder</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Gillett</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Hanby</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Easton</surname>
<given-names>D</given-names>
</string-name> &#x00026; <string-name>
<surname>Lakhani</surname>
<given-names>SR</given-names>
</string-name> (<year>2007</year>) <article-title>Basal&#x02010;like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long&#x02010;term survival</article-title>. <source>Breast Cancer Res</source>
<volume>9</volume>, <fpage>R4</fpage>.<pub-id pub-id-type="pmid">17217540</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="febs70033-cit-0027">
<string-name>
<surname>Lambert</surname>
<given-names>AW</given-names>
</string-name> &#x00026; <string-name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</string-name> (<year>2021</year>) <article-title>Linking EMT programmes to normal and neoplastic epithelial stem cells</article-title>. <source>Nat Rev Cancer</source>
<volume>21</volume>, <fpage>325</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">33547455</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="febs70033-cit-0028">
<string-name>
<surname>Chaffer</surname>
<given-names>CL</given-names>
</string-name> &#x00026; <string-name>
<surname>Weinberg</surname>
<given-names>RA</given-names>
</string-name> (<year>2011</year>) <article-title>A perspective on cancer cell metastasis</article-title>. <source>Science</source>
<volume>331</volume>, <fpage>1559</fpage>&#x02013;<lpage>1564</lpage>.<pub-id pub-id-type="pmid">21436443</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="febs70033-cit-0029">
<string-name>
<surname>Cynthia</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Younes</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Laucirica</surname>
<given-names>R</given-names>
</string-name> &#x00026; <string-name>
<surname>Rosen</surname>
<given-names>JM</given-names>
</string-name> (<year>1997</year>) <article-title>Overexpression of C/EBP &#x02010;LIP, a naturally occurring, dominant&#x02010;negative transcription factor, in human breast cancer</article-title>. <source>J Natl Cancer Inst</source>
<volume>89</volume>, <fpage>1887</fpage>&#x02013;<lpage>1891</lpage>.<pub-id pub-id-type="pmid">9414177</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="febs70033-cit-0030">
<string-name>
<surname>Milde&#x02010;Langosch</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>L&#x000f6;ning</surname>
<given-names>T</given-names>
</string-name> &#x00026; <string-name>
<surname>Bamberger</surname>
<given-names>A&#x02010;M</given-names>
</string-name> (<year>2003</year>) <article-title>Expression of the CCAAT/enhancer&#x02010;binding proteins C/EBP&#x003b1;, C/EBP&#x003b2; and C/EBP&#x003b4; in breast cancer: correlations with clinicopathologic parameters and cell&#x02010;cycle regulatory proteins</article-title>. <source>Breast Cancer Res Treat</source>
<volume>79</volume>, <fpage>175</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">12825852</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="febs70033-cit-0031">
<string-name>
<surname>Calkhoven</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>C</given-names>
</string-name> &#x00026; <string-name>
<surname>Leutz</surname>
<given-names>A</given-names>
</string-name> (<year>2000</year>) <article-title>Translational control of C/EBPalpha and C/EBPbeta isoform expression</article-title>. <source>Genes Dev</source>
<volume>14</volume>, <fpage>1920</fpage>&#x02013;<lpage>1932</lpage>.<pub-id pub-id-type="pmid">10921906</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="febs70033-cit-0032">
<string-name>
<surname>Ackermann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hartleben</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mastrobuoni</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Groth</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sterken</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Zaini</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Youssef</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Zuidhof</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Krauss</surname>
<given-names>SR</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2019</year>) <article-title>C/EBPbeta&#x02010;LIP induces cancer&#x02010;type metabolic reprogramming by regulating the let&#x02010;7/LIN28B circuit in mice</article-title>. <source>Commun Biol</source>
<volume>2</volume>, <fpage>208</fpage>.<pub-id pub-id-type="pmid">31240246</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="febs70033-cit-0033">
<string-name>
<surname>Sterken</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Ackermann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zuidhof</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Kortman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hernandez&#x02010;Segura</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Broekhuis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Spierings</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Guryev</surname>
<given-names>V</given-names>
</string-name> &#x00026; <string-name>
<surname>Calkhoven</surname>
<given-names>CF</given-names>
</string-name> (<year>2022</year>) <article-title>C/EBP&#x003b2; isoform&#x02010;specific regulation of migration and invasion in triple&#x02010;negative breast cancer cells</article-title>. <source>Npj Breast Cancer</source>
<volume>8</volume>, <fpage>11</fpage>.<pub-id pub-id-type="pmid">35042889</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="febs70033-cit-0034">
<string-name>
<surname>Tsukada</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kominato</surname>
<given-names>Y</given-names>
</string-name> &#x00026; <string-name>
<surname>Auron</surname>
<given-names>PE</given-names>
</string-name> (<year>2011</year>) <article-title>The CCAAT/enhancer (C/EBP) family of basic&#x02010;leucine zipper (bZIP) transcription factors is a multifaceted highly&#x02010;regulated system for gene regulation</article-title>. <source>Cytokine</source>
<volume>54</volume>, <fpage>6</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">21257317</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="febs70033-cit-0035">
<string-name>
<surname>Nerlov</surname>
<given-names>C</given-names>
</string-name> (<year>2007</year>) <article-title>The C/EBP family of transcription factors: a paradigm for interaction between gene expression and proliferation control</article-title>. <source>Trends Cell Biol</source>
<volume>17</volume>, <fpage>318</fpage>&#x02013;<lpage>324</lpage>.<pub-id pub-id-type="pmid">17658261</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="febs70033-cit-0036">
<string-name>
<surname>Subramanian</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tamayo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mootha</surname>
<given-names>VK</given-names>
</string-name>, <string-name>
<surname>Mukherjee</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ebert</surname>
<given-names>BL</given-names>
</string-name>, <string-name>
<surname>Gillette</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Paulovich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pomeroy</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Golub</surname>
<given-names>TR</given-names>
</string-name>, <string-name>
<surname>Lander</surname>
<given-names>ES</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2005</year>) <article-title>Gene set enrichment analysis: a knowledge&#x02010;based approach for interpreting genome&#x02010;wide expression profiles</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>102</volume>, <fpage>15545</fpage>&#x02013;<lpage>15550</lpage>.<pub-id pub-id-type="pmid">16199517</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="febs70033-cit-0037">
<string-name>
<surname>Koedoot</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Fokkelman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rogkoti</surname>
<given-names>VM</given-names>
</string-name>, <string-name>
<surname>Smid</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>van de Sandt</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>de Bont</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pont</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Klip</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Wink</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Timmermans</surname>
<given-names>MA</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2019</year>) <article-title>Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes</article-title>. <source>Nat Commun</source>
<volume>10</volume>, <fpage>2983</fpage>.<pub-id pub-id-type="pmid">31278301</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="febs70033-cit-0038">
<string-name>
<surname>Ren</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ji</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ye</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>L</given-names>
</string-name> &#x00026; <string-name>
<surname>Cai</surname>
<given-names>X</given-names>
</string-name> (<year>2023</year>) <article-title>The m6A demethylase FTO promotes keloid formation by up&#x02010;regulating COL1A1</article-title>. <source>Ann Translat Med</source>
<volume>11</volume>, <fpage>15</fpage>.</mixed-citation></ref><ref id="febs70033-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="febs70033-cit-0039">
<string-name>
<surname>Loayza&#x02010;Puch</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Rooijers</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Buil</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Zijlstra</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Oude Vrielink</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Lopes</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ugalde</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>van Breugel</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hofland</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Wesseling</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2016</year>) <article-title>Tumour&#x02010;specific proline vulnerability uncovered by differential ribosome codon reading</article-title>. <source>Nature</source>
<volume>530</volume>, <fpage>490</fpage>&#x02013;<lpage>494</lpage>.<pub-id pub-id-type="pmid">26878238</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="febs70033-cit-0040">
<string-name>
<surname>Sterken</surname>
<given-names>BA</given-names>
</string-name>, <string-name>
<surname>Ackermann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Muller</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zuidhof</surname>
<given-names>HR</given-names>
</string-name>, <string-name>
<surname>Kortman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hernandez&#x02010;Segura</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Broekhuis</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Spierings</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Guryev</surname>
<given-names>V</given-names>
</string-name> &#x00026; <string-name>
<surname>Calkhoven</surname>
<given-names>CF</given-names>
</string-name> (<year>2022</year>) <article-title>C/EBPbeta isoform&#x02010;specific regulation of migration and invasion in triple&#x02010;negative breast cancer cells</article-title>. <source>NPJ Breast Cancer</source>
<volume>8</volume>, <fpage>11</fpage>.<pub-id pub-id-type="pmid">35042889</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="febs70033-cit-0041">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name> &#x00026; <string-name>
<surname>Cui</surname>
<given-names>Q</given-names>
</string-name> (<year>2016</year>) <article-title>SRAMP: prediction of mammalian N6&#x02010;methyladenosine (m6A) sites based on sequence&#x02010;derived features</article-title>. <source>Nucleic Acids Res</source>
<volume>44</volume>, <elocation-id>e91</elocation-id>.<pub-id pub-id-type="pmid">26896799</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="febs70033-cit-0042">
<string-name>
<surname>Linder</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Grozhik</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Olarerin&#x02010;George</surname>
<given-names>AO</given-names>
</string-name>, <string-name>
<surname>Meydan</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mason</surname>
<given-names>CE</given-names>
</string-name> &#x00026; <string-name>
<surname>Jaffrey</surname>
<given-names>SR</given-names>
</string-name> (<year>2015</year>) <article-title>Single&#x02010;nucleotide&#x02010;resolution mapping of m6A and m6Am throughout the transcriptome</article-title>. <source>Nat Methods</source>
<volume>12</volume>, <fpage>767</fpage>&#x02013;<lpage>772</lpage>.<pub-id pub-id-type="pmid">26121403</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="febs70033-cit-0043">
<string-name>
<surname>Meyer</surname>
<given-names>KD</given-names>
</string-name> (<year>2019</year>) <article-title>DART&#x02010;seq: an antibody&#x02010;free method for global m6A detection</article-title>. <source>Nat Methods</source>
<volume>16</volume>, <fpage>1275</fpage>&#x02013;<lpage>1280</lpage>.<pub-id pub-id-type="pmid">31548708</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="febs70033-cit-0044">
<string-name>
<surname>Molinie</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lim</surname>
<given-names>KS</given-names>
</string-name>, <string-name>
<surname>Hillebrand</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Van Wittenberghe</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Howard</surname>
<given-names>BD</given-names>
</string-name>, <string-name>
<surname>Daneshvar</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mullen</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Dedon</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Xing</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2016</year>) <article-title>m6A&#x02010;LAIC&#x02010;seq reveals the census and complexity of the m6A epitranscriptome</article-title>. <source>Nat Methods</source>
<volume>13</volume>, <fpage>692</fpage>&#x02013;<lpage>698</lpage>.<pub-id pub-id-type="pmid">27376769</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="febs70033-cit-0045">
<string-name>
<surname>Mauer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Blanjoie</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Jiao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Grozhik</surname>
<given-names>AV</given-names>
</string-name>, <string-name>
<surname>Patil</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Linder</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Pickering</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Vasseur</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Q</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2017</year>) <article-title>Reversible methylation of m(6)Am in the 5&#x02032; cap controls mRNA stability</article-title>. <source>Nature</source>
<volume>541</volume>, <fpage>371</fpage>&#x02013;<lpage>375</lpage>.<pub-id pub-id-type="pmid">28002401</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="febs70033-cit-0046">
<string-name>
<surname>Sun</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Meng</surname>
<given-names>H</given-names>
</string-name> &#x00026; <string-name>
<surname>Yi</surname>
<given-names>C</given-names>
</string-name> (<year>2021</year>) <article-title>M(6)Am&#x02010;seq reveals the dynamic m(6)Am methylation in the human transcriptome</article-title>. <source>Nat Commun</source>
<volume>12</volume>, <fpage>4778</fpage>.<pub-id pub-id-type="pmid">34362929</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="febs70033-cit-0047">
<string-name>
<surname>Zhou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Shu</surname>
<given-names>XE</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>XM</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Hess</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Bruning</surname>
<given-names>JC</given-names>
</string-name> &#x00026; <string-name>
<surname>Qian</surname>
<given-names>SB</given-names>
</string-name> (<year>2018</year>) <article-title>N(6)&#x02010;Methyladenosine guides mRNA alternative translation during integrated stress response</article-title>. <source>Mol Cell</source>
<volume>69</volume>, <fpage>636</fpage>&#x02013;<lpage>647</lpage>.<pub-id pub-id-type="pmid">29429926</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="febs70033-cit-0048">
<string-name>
<surname>Vattem</surname>
<given-names>KM</given-names>
</string-name> &#x00026; <string-name>
<surname>Wek</surname>
<given-names>RC</given-names>
</string-name> (<year>2004</year>) <article-title>Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cells</article-title>. <source>Proc Natl Acad Sci</source>
<volume>101</volume>, <fpage>11269</fpage>&#x02013;<lpage>11274</lpage>.<pub-id pub-id-type="pmid">15277680</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="febs70033-cit-0049">
<string-name>
<surname>Ingolia</surname>
<given-names>NT</given-names>
</string-name> (<year>2016</year>) <article-title>Ribosome footprint profiling of translation throughout the genome</article-title>. <source>Cell</source>
<volume>165</volume>, <fpage>22</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">27015305</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="febs70033-cit-0050">
<string-name>
<surname>Boissel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Reish</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Proulx</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kawagoe&#x02010;Takaki</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sedgwick</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Yeo</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Meyre</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Golzio</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Molinari</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Kadhom</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2009</year>) <article-title>Loss&#x02010;of&#x02010;function mutation in the dioxygenase&#x02010;encoding FTO gene causes severe growth retardation and multiple malformations</article-title>. <source>Am J Hum Genet</source>
<volume>85</volume>, <fpage>106</fpage>&#x02013;<lpage>111</lpage>.<pub-id pub-id-type="pmid">19559399</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="febs70033-cit-0051">
<string-name>
<surname>Zidek</surname>
<given-names>LM</given-names>
</string-name>, <string-name>
<surname>Ackermann</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hartleben</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Eichwald</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kortman</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kiehntopf</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leutz</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Sonenberg</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>ZQ</given-names>
</string-name>, <string-name>
<surname>von Maltzahn</surname>
<given-names>J</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. (<year>2015</year>) <article-title>Deficiency in mTORC1&#x02010;controlled C/EBPbeta&#x02010;mRNA translation improves metabolic health in mice</article-title>. <source>EMBO Rep</source>
<volume>16</volume>, <fpage>1022</fpage>&#x02013;<lpage>1036</lpage>.<pub-id pub-id-type="pmid">26113365</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="febs70033-cit-0052">
<string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Su</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Y</given-names>
</string-name> &#x00026; <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name> (<year>2022</year>) <article-title>FTO in cancer: functions, molecular mechanisms, and therapeutic implications</article-title>. <source>Trends Cancer</source>
<volume>8</volume>, <fpage>598</fpage>&#x02013;<lpage>614</lpage>.<pub-id pub-id-type="pmid">35346615</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="febs70033-cit-0053">
<string-name>
<surname>Cubillos&#x02010;Rojas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Amair&#x02010;Pinedo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Tato</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Bartrons</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ventura</surname>
<given-names>F</given-names>
</string-name> &#x00026; <string-name>
<surname>Rosa</surname>
<given-names>JL</given-names>
</string-name> (<year>2019</year>) <article-title>Tris&#x02010;acetate polyacrylamide gradient gels for the simultaneous electrophoretic analysis of proteins of very high and low molecular mass</article-title>. <source>Methods Mol Biol</source>
<volume>1855</volume>, <fpage>269</fpage>&#x02013;<lpage>277</lpage>.<pub-id pub-id-type="pmid">30426423</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="febs70033-cit-0054">
<string-name>
<surname>McGlincy</surname>
<given-names>NJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Ingolia</surname>
<given-names>NT</given-names>
</string-name> (<year>2017</year>) <article-title>Transcriptome&#x02010;wide measurement of translation by ribosome profiling</article-title>. <source>Methods</source>
<volume>126</volume>, <fpage>112</fpage>&#x02013;<lpage>129</lpage>.<pub-id pub-id-type="pmid">28579404</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="febs70033-cit-0055">
<string-name>
<surname>Zhong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Karaletsos</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Drewe</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Sreedharan</surname>
<given-names>VT</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wendel</surname>
<given-names>H&#x02010;G</given-names>
</string-name> &#x00026; <string-name>
<surname>R&#x000e4;tsch</surname>
<given-names>G</given-names>
</string-name> (<year>2017</year>) <article-title>RiboDiff: detecting changes of mRNA translation efficiency from ribosome footprints</article-title>. <source>Bioinformatics</source>
<volume>33</volume>, <fpage>139</fpage>&#x02013;<lpage>141</lpage>.<pub-id pub-id-type="pmid">27634950</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="febs70033-cit-0056">
<string-name>
<surname>Martin</surname>
<given-names>M</given-names>
</string-name> (<year>2011</year>) <article-title>Cutadapt removes adapter sequences from high&#x02010;throughput sequencing reads</article-title>. <source>EMBnetjournal</source>
<volume>17</volume>, <fpage>10</fpage>&#x02013;<lpage>12</lpage>.</mixed-citation></ref><ref id="febs70033-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="febs70033-cit-0057">
<string-name>
<surname>Kim</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Langmead</surname>
<given-names>B</given-names>
</string-name> &#x00026; <string-name>
<surname>Salzberg</surname>
<given-names>SL</given-names>
</string-name> (<year>2015</year>) <article-title>HISAT: a fast spliced aligner with low memory requirements</article-title>. <source>Nat Methods</source>
<volume>12</volume>, <fpage>357</fpage>&#x02013;<lpage>360</lpage>.<pub-id pub-id-type="pmid">25751142</pub-id>
</mixed-citation></ref><ref id="febs70033-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="febs70033-cit-0058">
<string-name>
<surname>Robinson</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>McCarthy</surname>
<given-names>DJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Smyth</surname>
<given-names>GK</given-names>
</string-name> (<year>2010</year>) <article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title>. <source>Bioinformatics</source>
<volume>26</volume>, <fpage>139</fpage>&#x02013;<lpage>140</lpage>.<pub-id pub-id-type="pmid">19910308</pub-id>
</mixed-citation></ref></ref-list></back></article>